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Abstract 
Machado-Joseph Disease (MJD) is a neurodegenerative disorder included in 
the group of polyglutamine (polyQ) expansion diseases caused by an expansion of the 
polyQ tract of Ataxin-3 (Atx-3). This protein possesses a globular domain termed 
Josephin Domain (JD), which contains aggregation-prone regions (APRs) required for 
the initial steps of aggregation, a process independent of the polyQ expansion. A few 
interacting partners of Atx-3 are known to modulate the aggregation rate by protecting 
these APRs. With this knowledge, this work focused on elucidating the potential of 
nanobodies (NB) (antigen-binding domain derived from camelid heavy-chain 
antibodies) produced against the JD in the modulation of the aggregation process of 
Atx-3. 
After production and screening of 17 different NBs the four most promising were 
selected for further investigation of their biochemical and biophysical properties. The 
affinity of the interaction between NB01, 02 or 05 and different Atx-3 truncation variants 
(Atx-3 D1) and isoforms (Atx-3 13Q and 77Q) was determined to be in nanomolar 
range. NB03 showed no interaction and was used as a negative binding control. 
Combining Dynamic Light Scattering and Small Angle X-ray Scattering it was possible 
to observe a structural change in Atx-3 caused by the presence of a NB: while Atx-3 
naturally displays an elongated structure the complex (Atx-3 13Q:NB01) presents a 
more globular shape upon binding of two NB molecules. 
When exploring the ability of these NBs to modulate the aggregation process of  
Atx-3 it was concluded that their presence interfered with the self-assembly of the 
protein, increasing the lag phase of aggregation. Also, the morphology of mature 
amyloid fibrils present in the endpoint of the aggregation assay was modified by 
incubation with the NBs. However, intermediate species such as toxic oligomers or 
protofibrils are still detected. NB01 showed a significant impact in slowing down 
aggregation at a ratio of 1:2 (Atx-3:NB01). Additionally, NB05 presented a strong effect 
on the aggregation of expanded Atx-3 77Q without affecting normal Atx-3 13Q. As 
such, the latter may be an asset in the therapy against pathological Atx-3.  
Ultimately, results show that NBs are a promising tool in the therapeutic 
research of Machado-Joseph Disease and open a novel approach in the study of this 
disease. 
Keywords:  
Neurodegeneration, Machado-Joseph Disease, Ataxin-3, Polyglutamine tract, Josephin 
Domain, Dynamic Conformation, Aggregation-prone Region, Protein Aggregation,  
Self-assembly, Amyloid Fibril, Oligomers, Modulation of Aggregation, Nanobodies.  
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Resumo 
A doença de Machado-Joseph (MJD) é uma doença neurodegenerativa em que 
uma das causas para os sintomas corresponde à acumulação da proteína  
Ataxina-3 (Atx-3) quando esta apresenta uma expansão na região de poliglutaminas 
(polyQ). Esta proteína apresenta um domínio globular, Domínio Josefina (JD), que 
contempla regiões propensas a agregar (APR) responsáveis pelos primeiros passos 
de agregação, independentemente da expansão de polyQ. Recentemente, têm sido 
identificadas algumas proteínas capazes de se ligar ao JD como moduladoras da 
agregação da Atx-3, exercendo uma proteção das APR. Deste modo, definimos como 
objetivo deste trabalho o estudo das potencialidades do uso de nanobodies (NB) 
(domínio de ligação ao antigénio derivados de anticorpos de cadeia pesada de 
camelídeos) produzidos contra o JD para avaliar o efeito dos mesmos na modulação 
da agregação da Atx-3.  
Após a produção de 17 NBs, os 4 mais promissores foram selecionados e as 
propriedades bioquímicas e biofísicas caracterizadas. As afinidades da interação entre 
os NB01, 02 e 05 com formas truncadas (Atx-3 D1) ou isoformas (Atx-3 13Q e 77Q) da  
Atx-3 foram determinadas na escala dos nanomolar, não tendo sido possível detetar 
interação com o NB03 que foi subsequentemente usado com controlo negativo. 
Combinando os dados de Dynamic Light Scattering (DLS) e Small Angle X-Ray 
Scattering (SAXS) foi possível denotar que enquanto que a Atx-3 apresenta 
naturalmente uma estrutura alongada, a presença de duas moléculas de NB01 torna o 
complexo mais globular. Com o estudo da capacidade de modulação destes NBs na 
agregação da Atx-3 ficou concluído que de facto estes interferem com a 
oligomerização da proteína, aumentando o tempo da lag-phase da agregação. As 
fibras maduras presentes no final do processo de agregação são alteradas com a 
incubação com os NBs. No entanto, espécies oligoméricas intermediárias continuam 
presentes. 
O NB01 apresentou um impacto significativo no atraso do início da agregação 
num rácio de 1:2 (Atx-3:NB). Ainda, o NB05 mostrou um maior efeito na modulação da 
agregação na Atx-3 expandida sem alterar a agregação da proteína normal, 
demonstrando o seu potencial na terapia da doença. Os NBs aqui estudados 
apresentam-se então como moléculas promissoras para estudos na doença de MJD. 
Palavras-Chave: 
Neurodegeneração, Doença de Machado-Joseph, Ataxina-3, expansão de 
poliglutaminas, Domínio Josefina, Conformação dinâmica, propenso à agregação, 
agregação, oligomerização, fibras de amiloide, oligómeros, modulação da agregação, 
nanobodies. 
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Introduction 
Protein Misfolding  
Proteins perform crucial functions in nearly all biological processes. They are 
responsible for cellular homeostasis as catalysts, having functions in DNA repair, 
intercellular communication, transport and molecule storage, providing mechanical 
support and immune protection, among many other functions. 
To accomplish their suitable biological function, polypeptides require folding 
from a random coil structure (after translation) to a native state (three-dimensional 
functional state). Acquiring a native structure is usually essential for protein function, 
but in some cases specific protein domains (or even whole proteins) remain unfolded to 
achieving their biological function.  
Folding errors may lead to the formation of misfolded and inactive proteins 
which might accumulate and interfere with cellular homeostasis1. Many studies have 
been performed to understand the nature of protein folding mechanisms and energy 
landscapes are nowadays used to describe them (Figure 1). The energy landscape 
profile regards a dynamic process between the folded and unfolded states. During 
folding, the protein procures the lowest energy conformation (native state). Structural 
fluctuations of the native state may induce temporarily less-folded conformations 
(partially folded states) that might trigger protein aggregation2,3.   
 
 
Figure 1: Energy landscape scheme for protein folding and aggregation. The vast conformational states of an 
unfolded protein merge into a native state via establishment of intramolecular contacts. The exposure of some 
aggregation-prone regions may lead to intermolecular contacts forming aggregated species with decreasing energy, 
such as oligomers, amorphous aggregates and at last amyloid fibrils. These amyloid fibrils possess the lowest energy 
possible, which makes this state very unlikely to reverse back to a native one 
4
. 
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Small proteins with less than 100 amino acids reach their native conformation 
with a simple energy landscape and in a sub-second timescale4-6. However, larger 
proteins have a larger timescale to achieve the native conformation with many 
intermediate states. Depending on the energy of the intermediate states it can be 
easier or more difficult to fold back into the native structure7. Besides, these 
intermediate conformations may expose some key regions (aggregation-prone regions) 
that are required to trigger an aggregation event. 
These aggregated conformations may work additionally as a template for further 
protein aggregation, unbalancing the system. 
  
Polyglutamine Diseases 
Giving the appropriate conditions, most proteins have the ability to self-
assemble into amyloid fibrils, yet only an exclusive group of proteins appear to 
aggregate under physiological conditions8,9.  
A protein’s ability to aggregate and form organized amyloid-like structures is 
affected by the amino acid sequence. Proteins with trinucleotide repeats, specifically 
containing polyglutamines (polyQ), are an extraordinary rarity in the self-assembly 
protein group. Glutamines are polar residues stabilized by solvent interaction, but it has 
been demonstrated that isolated polyQ peptides can form insoluble amyloid fibrils in 
solution10. Due to this fact, polyQ repeats are associated with some neurodegenerative 
disorders designated as polyglutamine diseases.  
Polyglutamine expansion diseases constitute a group of hereditary 
neurodegenerative disorders caused by the expansion of CAG trinucleotide repeats 
above a certain threshold. The gene expansion is translated into a protein with an 
expanded polyQ tract.  
There are at least nine different polyQ proteins associated with rare 
neurodegenerative disorders with a mean frequency of 1-10 cases per 100.000 
people11: Huntingtin (Htt) in Huntington’s disease (HD)12; ataxin-1 (Atx-1), ataxin-2 (Atx-
2), ataxin-3 (Atx-3), voltage-dependent calcium channel α-1A subunit (CACNA1A), 
ataxin-7 (Atx-7) and TATA-binding protein (TBP) in Spinocerebellar Ataxias SCA112, 
SCA213, SCA3 (also called Machado-Joseph disease, MJD)14, SCA615, SCA716 and 
SCA1717; atrophin-1 (Atn1) in Dentatorubral-Pallidoluysian Atrophy (DRPLA)18,19 and 
Androgen Receptor (AR) in Spinal-Bulbal Muscular Atrophy (SBMA)20.  
Although the proteins related to these diseases share no homology besides the 
polyQ repeats21 the expansion of the polyQ tract leads to their aggregation and specific 
accumulation in neuronal cells as inclusions, with consequent neuronal loss as well as 
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other physical and neurologic manifestations. Still, each polyQ disease exhibits specific 
symptoms which usually begin in mid-life and progress over 10 to 30 years, leading 
ultimately to the patient’s death22,23. 
All polyQ diseases have a shared negative correlation between the age onset 
and the CAG repeats. A greater glutamine repeats number results in an earlier 
development of the disease. This shows that the glutamine tract plays a central role in 
the progression of the disease.  
Some variability in the polyQ repeats length exists. However, expansion beyond 
a certain threshold, distinct for each polyQ protein (Table 1), enhances the propensity 
to form -rich amyloid-like fibrils24-28. 
Table 1: Human diseases associated with CAG codon repeats adapted from
29
.  
Disease Gene 
Normal  
polyQ Repeats 
Pathogenic  
polyQ repeats 
Huntington’s  
disease (HD) 
HTT (Huntingtin) 6 – 34 36 – 121 
Spinocerebellar ataxia Type 1 
 (SCA1) 
ATXN1 6 – 39 40 – 82 
Spinocerebellar ataxia Type 2 
(SCA2) 
ATXN2 15 – 24 32 – 200 
Spinocerebellar ataxia Type 3  
 or Machado-Joseph disease 
(SCA3 or MJD) 
ATXN3 10 – 51 55 – 87 
Spinocerebellar ataxia Type 6 
(SCA6) 
CACNA1A 4 – 20 20 – 29 
Spinocerebellar ataxia Type 7 
(SCA7) 
ATXN7 4 – 35 37 – 306 
Spinocerebellar ataxia Type 
17 (SCA17) 
TBP 25 – 42 47 – 63 
 Dentatorubral-Pallidoluysian 
Atrophy (DRPLA) 
ATN1  7 – 34 49 – 88 
Spinal-Bulbal Muscular  
Atrophy (SBMA) 
Androgen 
receptor on X 
chromosome 
6 – 34 36 – 121 
 
Machado-Joseph Disease 
Machado-Joseph disease (MJD) was described in Portuguese descendants 
from the Azores islands30-32 and corresponds to the most common autosomal dominant 
 spinocerebellar ataxia and the second most frequent polyQ disease, after HD33-35. 
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This neurodegenerative disease involves neuronal loss in selective brain 
regions, including the cerebellum (spinocerebellar pathways and dentate nucleus), 
brainstem, (pons and medulla oblongata) basal ganglia (globus pallidus, caudate and 
putamen, substantia nigra) and spinal cords32,36-39. Common features of MJD are 
progressive cerebellar ataxia, pyramidal signs, as well as ophthalmoplegia, dystonia, 
dysphagia and facial and speaking movement problems40,41. 
The gene responsible for the disease (MJD1 or ATX3) is mapped on the long 
arm of the chromosome 14, region 14q31.114. In the case of MJD, the polyQ of Atx-3 of 
healthy individuals has up to 44 glutamines and repeats between 45 and 51 are 
associated with an incomplete penetrance of the disease14,37,42. It then manifests when 
the repeat length surpasses the threshold of 53 glutamines43,44. 
 
Ataxin-3 Architecture  
Atx-3 is a multidomain protein with deubiquitinase (DUB) activity involved in 
central cellular processes, such as transcriptional regulation, signal transduction and 
cell quality control45. The protein is composed by a conserved globular domain at the  
N-terminal, the Josephin Domain, (JD, amino acids  1-170) (Figure 2, green box) and a 
flexible C-terminal tail46. The C-terminus comprehends two tandem ubiquitin-interacting 
motifs (UIM1-2) (Figure 2, yellow boxes) followed by the polyQ region of variable length 
(Figure 2, red box)47. Depending on the splicing variant, the C-terminal region has a 
third UIM (UIM3) (Figure 2, yellow box)48.  
 
Figure 2: Representation of the domain architecture of Atx-3 evidencing the aggregation-prone region and the 
3D atomic structures of some regions. Detailed representation of Atx-3 isoform UIM3 composed by the globular 
Josephin domain (JD – light green) evidencing the aggregation-prone region (APR – dark green) and the flexible C-
terminal with three ubiquitin interaction motifs (UIM – yellow), a nuclear localization sequence (NLS – grey) and the 
expandable polyglutamine tail (polyQ – red). In the top of the scheme are cartoon representations of JD (PDB 
accession: 1YZB), UIM1-2 (PBD accession: 2KLZ) and the PolyQ tract (PDB accession: 4WTH). 
 
N-terminal C-terminal 
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The isoform containing the UIM3 is the predominant variant in the brain49. 
Finally, a nuclear localization signal (NLS) (Figure 2, in grey) is located upstream of the 
polyQ region50.  
The three-dimensional structure of Atx-3 has not been determined but there are 
structural information regarding some of its regions. The JD has a globular papain-like 
fold with a high -helical content46,51. A catalytic triad is formed in the active site pocket 
by structurally conserved amino acids C14, H119, N13452-54. Structures of the UIM1-2 
region revealed a -helical conformation induced by the presence of ubiquitin55. Crystal 
structures of the C-terminus with a small segment of the polyQ expansion show some 
evidence of the conformation flexibility of this region56. PolyQ expansion does not 
mediate global structural changes, only local conformational changes have been 
detected. These subtle changes may be the cause for faster aggregation observed in 
expanded Atx-324,51,57,58. 
 
Ataxin-3 Aggregation Pathway  
PolyQ expansion disorders are linked to the formation of extracellular amyloid 
deposits or intracellular inclusions with amyloid-like characteristics25,59. 
Both non-expanded Atx-3 and the isolated JD have an intrinsic propensity to  
self-assemble and form amyloid-like fibrils, demonstrating a polyQ-independent 
aggregation process58,60-62. Some specific regions of JD are responsible for triggering 
the aggregation. These aggregation-prone regions (APRs) can be predicted by 
bioinformatic analysis of the protein sequence. 63-75 The APRs of Atx-3 are located 
between residues 73 and 96 (Figure 2, dark green box). This was experimentally 
validated using limited proteolysis and mass spectrometry by Scarff and colleagues58. 
Usually, these APR are hidden in hydrophobic regions inside the protein 
preventing the start of aggregation. However, mutations such as the polyQ expansion 
increase the probability of these APR becoming exposed to the solvent. A two-step 
process was proposed for the aggregation of Atx-3. The first one is mediated by the 
APR of JD (independent of the polyQ tract) followed by a second step that is related to 
the polyQ expansion which results in mature SDS-resistant fibrils58,76. Aggregation of 
Atx-3 starts with a self-assembly of JD. Self-association initiates by exposure of the 
APR (amino acid 73 to 96) in the globular domain (Figure 2 and Figure 3, dark 
green)58. In solution, the JD is in a conformational equilibrium and the APR may 
become exposed, initiating the aggregation process. The increased rate of aggregation 
in expanded Atx-3 can be explained by dynamic fluctuations that expose the APR more 
frequently57,58. 
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Figure 3: Model of the mechanism of fibril formation of non-expanded and pathogenic Atx-3.  The equilibrium 
conformation in the JD leads (sporadically) to the exposure of its APR. The polyQ expansion increases the likelihood of 
this exposure resulting in a faster aggregation. This leads to the formation of dimers creating a template for further 
monomer addition, ultimately creating protofibrils. In non-expanded polyQ these protofibrils are SDS-sensitive. In the 
case of expanded Atx-3 the polyQ region can then interact by hydrogen bonds and form mature fibrils that are SDS 
resistant. Adapted from
58
. 
    
Self-assembly of monomers by the JD region leads to the formation of compact 
dimers that function as a nucleation point for the Atx-3 sequential monomer addition, 
resulting in the formation of elongated SDS-sensitive amyloid protofibrils (Figure 3A)58. 
Up to this point, the process in entirely independent of the polyQ tract and 
occurs in both normal and pathological Atx-3. The second stage of the aggregation 
mechanism involves only the expanded Atx-3 with the polyQ tract producing SDS-
resistant mature amyloid fibrils (Figure 3B). These amyloids fibrils are stabilized by the 
hydrogen bonds involving the glutamine side-chains76,77.   
The role of the UIMs in the two steps of aggregation is still under study. The 
isolated form of UIM1-2 does not aggregate, but the aggregation rate of JD is 
accelerated by its presence. These regions promote an electrostatic interaction 
between themselves, approximating the JD’s APRs to each other78. The presence of 
these APRs is not unique in Atx-3. In other polyQ proteins such as Atx-1 and Htt these 
regions have also been identified79-83. 
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PolyQ Proteins Oligomeric Species 
The accumulation of aggregated protein into insoluble amyloid deposits is the 
hallmark for several neurodegenerative disorders such as the polyQ diseases84 . In 
fact, the process of monomeric polyQ protein self-assembly into amyloid fibrils is being 
extensively studied (Figure 4A)10,85,86. The mechanism of amyloid formation occurs via 
a nucleation-dependent growth by a polymerization mechanism86-88. The global 
polymerization rate depends on three stages: a slow nucleation phase (lag phase) 
involving a thermodynamically unfavorable transition from the native form to a non- 
-native conformation which is then followed by its elongation. The latter happens by the 
exponential addition of fibril-precursors extending the fibril form (elongation phase). 
After elongation, there is a dynamic equilibrium in the amount of fibrils in the stationary 
phase.   
However, beyond the formation of fibrillar aggregates, cells also accumulate a 
variety of morphologically distinct species (Figure 4). Besides the aggregation process 
starting directly from a monomeric conformation (Figure 4A) the aggregation can also 
start from intermediary soluble oligomers that need structural reorganization to form 
fibrils (Figure 4B).89-92 The aforementioned mechanisms may occur simultaneously. 
Other intermediary species such as annular aggregates may also form (in- or  
off- pathway93), leading to final amorphous aggregates (Figure 4C). All these 
aggregated structures can accumulate and form large inclusions93. The fact that the 
endpoint structure is an agglomerate of aggregated species makes it very difficult to 
determine exactly which species is the toxic one. 
 
Neurotoxicity may be caused by the modification of regular function of the polyQ 
protein by the polyQ expansion94 and/or from the presence of toxic intermediate 
oligomers95-99. There is evidence that these intermediate oligomers interact with 
macromolecules present in the cells leading to a pronounced toxicity and amyloid fibrils 
work as a protection mechanism against these aberrant interactions100-103. 
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Figure 4: Schematic model of misfolded and aggregated protein with polyQ expansions. Monomeric protein 
assembles into inclusion bodies through distinct conformers on-pathway (in blue) or off-pathway (in red) to fibril 
formation. A) monomeric addition leading directly to fibril formation; B) fibril formation via oligomeric intermediates, (both 
mechanisms A and B can happen simultaneously); C) Off-pathway mechanism with different sized oligomers as annular 
aggregates and large amorphous structures. D) All these aggregated structures may accumulate and form large 
inclusions.
93
 
 
Modulation of Atx-3 Aggregation by Molecular Partners 
Besides the APRs and the polyQ region post-translational modifications (PTMs) 
can also mediate Atx-3 aggregation104,105. Additionally, aggregation may also be 
regulated by the presence of molecular partners29,106. Interaction of these with the 
polyQ or the APR may prevent the aggregation self-assembly but can also increase its 
rate and toxicity107,108. The protective effect is mediated by the interaction of said 
partners at or near the aggregation-prone region shielding the self-assembly 
sequences. Atx-3 JD also binds to ubiquitin besides UIM1 and UIM2 and due to the 
proximity of the APR this interaction delays the self-assembly47,52,109. Another example 
of this kind of modulation of aggregation is the interaction with the small heat shock 
protein alphaB-crystallin (αB-c) which modulates the first step of aggregation 
(independent of polyQ)110.  
Some small peptides show the ability of inhibiting aggregation in amylogenic 
diseases but since these peptides also contain short polyQ sequences they have the 
risk of accelerating Atx-3 aggregation and enhancing its toxicity. So, new strategies 
need to be developed.111  
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Nanobodies 
Antibodies such as conventional Immunoglobulin G (IgG) have been extensively 
used for the development of new therapies. IgG are tetramers of 150 kDa consisting on 
two identical heavy chains (50 kDa each) and 2 identical light chains (25 kDa each), 
linked by disulfide bonds112. However, there are some undesirable features related with 
their application, such as high production costs, large size and instability, prompting a 
search for new solutions. 
While the molecular structure of antibodies among mammals is highly 
conserved, small variations have been found. A good example is the heavy chain 
antibody, found in llamas and other camelids (camel, dromedary, vicuña, gunaco), 
which only exhibits a heavy chain, as the name suggests113. Like conventional 
antibodies (Figure 5A), heavy chain antibodies (Figure 5B) also possess a VH fragment 
which in this case is called VHH (variable domain of heavy chain antibody), responsible 
for epitope recognition. VHH can be cloned and recombinantly expressed as the 
smallest form of an antibody ( 15 kDa), thus being referred to as nanobody (NB) 114. 
 
 
Figure 5: Schematic representation of a conventional antibody, a heavy chain antibody from Camelidae and a 
Nanobody. A) Schematic representation of an IgG antibody and its segments. B) Schematic representation of a heavy-
chain antibody and its segments. C) Isolated variable heavy chain (VHH), or NB, from camelid Ig. D) X-ray structure of a 
VHH fragment. The complementarity determining regions (CDR) 1, 2 and 3 are shown in red, orange and yellow, 
respectively. The stick between CDR3 and CDR1 indicates a disulfide bond connecting these two regions.
115
 CH 
(constant heavy chain), CL (constant light chain), VH (variable heavy chain) and VL (variable light chain). 
 
The loop of NBs complementarity determining region 3 (CDR3) (Figure 5C and 
5D) is more extended than in the usual antibodies and folds over the hydrophobic 
amino acids in the surface increasing its solubility116.  Additionally, they present the 
same specificity of binding as a regular antibody117. 
NBs are easily expressed in E. coli as periplasmic proteins with a high yield. 
They are highly resistant to high temperatures and to pH variations. With these 
characteristics, they are an excellent tool to apply in both research and therapy118,119. 
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Applications of Nanobodies 
Due to all the characteristics just mentioned and their low molecular weight, low 
toxicity, reduced immunogenicity and high affinity, NBs can be applied in distinct fields 
of research. The applicability of NBs in crystallography as crystallization chaperones 
(stabilizing a conformation of the protein) has been noted: it was possible to obtain 
structures such as transient multiprotein assemblies120-123, membrane proteins120,124-126 
and intrinsically disordered proteins127,128 with the use of these molecules. 
NB have also proved to be a successful application in neurodegenerative 
disorders research. In this case, NBs are used to modulate the amyloid formation 
process and as a probe to study the intermediates formed during aggregation129,130.  
The ability of these antibodies to work as an anti-aggregation molecule has 
already been studied in amyloid disorders as the Huntington’s disease and in 
Parkinson’s disease: In Parkinson’s, NBs inhibited the formation of fibrils promoting a 
rapid conformational conversion into a less stable oligomer, reducing the oligomer-
induced cellular toxicity131. Regarding Huntington’s, studies showed that the application 
of antibodies in the N-terminal region of Huntingtin can modulate the aggregation 
mechanism both in vivo and in vitro132-134. The application of NBs in amyloid related 
diseases is therefore considered a promising in the study of aggregation inhibition.  
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Objectives 
Several studies have been recently performed to understand the mechanism of 
aggregation of Ataxin-3 (Atx-3) and its potential as the main target for the therapy of 
Machado-Joseph disease, which is still undeveloped. It has been demonstrated that 
interacting partners such as ubiquitin have the ability to bind Atx-3 near the 
aggregation--prone region (APR) and increase the lag phase of aggregation. The main 
intention of this work was to select successful Atx-3-binding molecules with a role in the 
modulation of Atx-3 aggregation. To achieve this goal four objectives were defined: 1) 
To express and purify 18 nanobodies raised against the Josephin domain of Atx-3 and 
pre-select successful Atx-3-binding candidates; 2) To characterize the molecular 
details of the selected NBs binding to Atx-3 by determination of the binding affinities, 
the Atx-3:NB complexes stoichiometry and the NBs binding site on Atx-3; 3) To 
evaluate the crystallization chaperon properties of the NBs on Atx-3; 4) To study their 
impact on the modulation of Atx-3 aggregation process. 
 
We wanted to address distinct questions. Is the binding of the NB specific to a 
single region of Atx-3? Do the NBs have an impact on the structure of Atx-3? Can 
these NBs increase the lag phase of Atx-3 aggregation, delaying the whole process 
and change the species formed in solution? Also, how do the NBs affect the toxicity of 
the oligomeric species and what is their potential as a therapeutic tool of MJD? 
Additionally, the ability of these NBs to work as a crystallization chaperone was 
explored in crystallization trials for Atx-3 hoping that the stabilization of an Atx-3 
conformation would help the crystallization process. 
 
To fulfill the objectives a set of experiments was designed using the following 
techniques: Isothermal Titration Calorimetry (ITC), Dynamic Light Scattering (DLS) and 
Small Angle X-ray Scattering (SAXS). To explore the pharmaceutical potential of the 
NBs in the aggregation process of Atx-3 and subsequent implications in the therapeutic 
research on Machado-Joseph disease we performed an Atx-3 aggregation time course 
with and without the presence of NBs as well as a fluorescence assay coupled with 
size exclusion chromatography and DLS. To assess the toxicity of the species formed 
at the endpoint of aggregation, samples were examined using Transmission Electron 
Microscopy, Dot-blot and a Filter Retardation Assay.  
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Material and Methods 
Reagents 
Media: 
Luria-Bertani solid medium (LB): 1 % (w/v) tryptone, 0.5 % (w/v) yeast extract,  
1 % (w/v) sodium chloride (NaCl), 1.5 % (w/v) of agar. 
Luria-Bertani broth medium with low osmolarity (LB-ON): 1 % (w/v) tryptone,  
0.5 % (w/v) yeast extract. 
Terrific Broth (TB): 1.2 % (w/v) tryptone, 2.4 % (w/v) yeast extract,  
0.4 % (w/v) glycerol, 0.23 % (w/v) potassium phosphate monobasic (KH2PO4),  
1.64 % (w/v) potassium phosphate dibasic (K2HPO4). 
Super Optimal Broth (SOB): 2 % (w/v) Tryptone peptone, 0.5 % (w/v) yeast,  
0.05 % (w/v) (NaCl) and 0.0186 % (w/v) potassium chloride (KCl). 
 
Buffers: 
Ataxin-3 purification buffers 
Cell lysis buffer: 20 mM sodium phosphate pH 7.5, 500 mM NaCl,  
2.5 % (w/v) glycerol, 20 mM imidazole, 50 g/mL lysozyme, 
50 g/mL desoxirribonuclease (DNase) I, 10 mM magnesium chloride (MgCl2) and 
10 mM phenylmethylsulfonyl fluoride (PMSF). 
Ni2+-charged HisTrap buffer A: 20 mM sodium phosphate pH 7.5, 500 mM NaCl,  
2.5 % (w/v) glycerol, 20 mM imidazole. 
Ni2+-charged HisTrap buffer B: 20 mM sodium phosphate pH 7.5, 500 mM NaCl,  
2.5 % (w/v) glycerol, 500 mM imidazole. 
Gel filtration buffer: 20 mM sodium phosphate pH 7.5, 150 mM NaCl,  
5 % (w/v) glycerol, 2 mM EDTA, 1 mM dithiothreitol (DTT). 
 
Nanobody purification buffers 
Cell lysis buffer: 0.2 M Tris pH 8.0, 0.5 M sucrose and EDTA-free protease inhibitor 
tablets (Thermo Fisher Scientific). 
Ni2+-charged HisTrap Buffer A: 50 mM sodium phosphate pH 7.0, 500 mM NaCl. 
Ni2+-charged HisTrap Buffer B: 50 mM sodium phosphate pH 7.0, 500 mM NaCl, 
300 mM imidazole. 
Gel filtration buffer: 50 mM sodium phosphate pH 7.5, 150 mM NaCl. 
 
Ataxin-3 aggregation buffer: 20 mM sodium phosphate pH 7.5, 150 mM NaCl,  
1 mM DTT. 
Isothermal Titration Calorimetry (ITC) buffer: 20 mM sodium phosphate pH 7.5, 
150 mM NaCl, 1 mM TCEP. 
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Bacterial Strains 
Table 2: List of Bacterial Strains and its genotype for plasmid replication (E. coli DH5) and for Atx-3 variants  
(E. coli BL21-SI) and NBs (E. coli WK6 (su-)) recombinant protein expression. 
Bacterial Strain Application Genotype 
E. coli DH5 
(Invitrogen) 
Plasmid 
 replication 
F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 
Φ80dlacZΔM15 deoR Δ(lacZYA-argF) 
U169 nupG, hsdR17(rK- mK+), λ– 
E. coli BL21-SI 
(Stratagene) 
Protein expression 
(Atx-3) 
F- ompTIon hsdSB (rB-, mB-) gal dcm 
endA1 proUp::T7 RNAP::malQ-lacZ (TetS) 
E. coli WK6 (su-) 
(Instruct) 
Protein expression 
(NB) 
Δ lac-proAB), galE, strA/F' lacIq,lacZΔM15, 
proA+B+] 
 
Plasmids 
Table 3: List of plasmids for Atx-3 and NBs expression with inductor and antibiotic resistance. 
Atx-3 JD pDEST17/J1-1 
Induction: 2xLB; 3M NaCl 
Resistance: Ampicilin 
Atx-3 D1 pDEST17_His6_Atx-3 D1 
Atx-3 13Q pDEST17_TevG_Atx-3 13Q 
Atx-3 77Q pDEST17_TevG_Atx-3 77Q 
NBs 
Info: GenBank KF415192 
pMESy4 
Induction: 1mM IPTG 
Resistance: Ampicilin 
 
Truncated variants and isoforms are displayed in Figure 6.  
 
Figure 6: Representation of Atx-3 isoforms and truncation variants used in this study. The globular JD (Atx-3 JD), 
the JD followed by two tandem ubiquitin interaction motifs (UIM1-2) (Atx-3 D1), the non-pathological full-length protein 
containing 13 glutamines (Atx-3 13Q) and a pathological isoform with an expansion of polyglutamine tract to 77 
glutamines (Atx-3 77Q). 
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In collaboration with European Instruct Platform Nanobodies4Instruc, 
conformational NBs against ataxin-3 (Atx-3) were produced by immunization of llamas 
with the Josephin domain (JD) of Atx-3135. The specificity of the NBs was tested by 
ELISA, and a total of 18 Atx-3-binding NBs were selected for further studies. 
 
   
Figure 7: Plasmid representation. A) Ataxin-3 variants plasmid (pDEST17) with T7 promotor, 6x HIS/TEVg and the 
gene conferring ampicillin resistance (AmpR). B) NBs plasmid (pMESy4), with a lac promotor (Plac/operator) and the 
Amp resistance gene (AmpR). The NB sequence is inserted in the pMESy4 plasmid between the pelB sequence 
(periplasm secretion signal) and a 6xHis-tag. 
 
 
Antibodies 
Table 4: Primary and secondary antibodies. Primary antibodies: 1H9 recognizes Atx-3 at the residues E214-L233, 
anti-OC recognizes amyloid fibrils/protofibrils, Anti-A11 is a conformational antibody that recognizes toxic oligomers. 
Secondary antibodies anti-mouse and anti-Rabbit with its concentration and incubation conditions. 
Primary antibody: Host Dilution Incubation 
Anti-Atx-3 1H9  
(MAB5360, Millipore) 
Mouse 
1:20.000 
TBS-T 3% BSA 
2h, RT 
Anti-Amyloid Fibrils  
OC136 (AB2286, Millipore) 
Rabbit 
1:50.000 
TBS-T, 3% BSA 
ON, 4 ºC 
Anti-Amyloid Oligomer 
A11137 (AB9234, Millipore) 
Rabbit 
1:000 
TBS-T, 3% BSA 
1h, RT 
    
Secondary antibody Host Dilution Incubation 
Anti-Rabbit HRP 
(A6154, Sigma-Aldrich) 
Mouse 
1:10.000 
TBS-T, 3% BSA 
1h, RT 
Anti-Mouse HRP 
(A4416, Sigma-Aldrich) 
Rabbit 
1:10.000 
TBS-T, 3% BSA 
1h, RT 
 
A B 
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Preparation of competent cells 
E. coli cells (DH5, BL21-SI and WK6(Su-)) were inoculated on a plate 
containing LB medium and grown overnight (ON) at 37 ºC (INCU-line, VWR). An 
isolated colony was picked and inoculated in 30 mL of LB medium at 37 ºC, 250 rpm 
for 6-8 hours (Shaker, IKA). Then 1 mL of the grown culture was inoculated in 250 mL 
of SOB and left ON at 18 ºC and 200 rpm (Shaker, IKA). When the culture reached 
OD600 0.6 the culture was kept in ice for 10 min and harvested at 2500 xg (Sorvall ST 
40, Thermo Fisher Scientific), 10 min, 4 ºC. The pellet was carefully resuspended in 
transformation buffer (0.238 % HEPES, 0.22 % CaCl2.2H2O, 1.864 % KCl at pH 6.7 
and 1.09 % of MnCl2.4H2O), kept on ice during 10 min and harvested again at 2500 xg, 
10 min, 4 ºC. The pellet was resuspended in transformation buffer and 1.5 mL of 
dimethyl sulfoxide (DMSO) were added drop by drop and kept during 10 min on ice. 
Aliquots of 200 L were frozen and stored at -80 ºC.  
 
Transformation of competent cells with plasmid DNA 
100 ng of plasmid DNA was added to 50 L of competent cells and incubated 
on ice for 30 minutes. Afterwards, the mix suffered a heat shock treatment for 45 sec at 
42 ºC, followed by a cold-shock during 10 min on ice. After that, 500 L of LB-ON 
medium was added, and the suspension was incubated at 37 ºC for 1 hour at 180 rpm  
(Shaker, IKA). The cells were then plated on LB-ON solid medium supplemented with 
ampicillin 100 mg/L and incubated ON at 37 ºC (Sigma-Aldrich). 
This procedure was followed by a plasmid DNA replication or a recombinant 
protein expression protocol as detailed below. 
 
Plasmid DNA Replication 
For plasmid DNA replication E. coli DH5 cells were used. An isolated colony of 
transformed cells was inoculated in 20 mL LB liquid medium and incubated ON at 
37 ºC, 180 rpm (Shaker, IKA). The next day, the cells were harvested at 3500 xg, 
10 min (Avanti J-26 XP - Rotor J-LITE JLA 8.1000, Beckman-Coulter) and the plasmid 
purification was performed using the commercial NZYMiniprep Kit (NZYtech – Gene 
and Enzymes) and following the manufacturer’s protocol. The plasmid concentration 
was determined at measuring the absorbance at 260 nm using the Nanodrop (Thermo 
Fisher Scientific). To detect any possible mutation during the replication process, 
nucleotide sequences of NBs were confirmed by direct sequencing of the plasmids 
(LightRun, GATC biotech). 
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Recombinant Protein Expression 
For the expression of Atx-3 and of the NBs E. coli BL21-SI and WK6(su-) cells, 
respectively, were used. BL21-SI cells were transformed with pDEST17 plasmid 
expressing 6His-Atx-3 (Atx-3 JD, Atx-3 D1 domain, full length Atx-3 13Q and expanded 
Atx-3 77Q). WK6(su-) were transformed with pMESy4 plasmid expressing 6His-NB.  
4 to 5 colonies of the transformed E. coli BL21-SI cells were resuspended in 
500 L of LB-ON medium and 100 L of inoculum was plated on LB-ON solid medium 
supplemented with 100 mg/L ampicillin (Sigma-Aldrich, USA) and incubated overnight 
at 37 ºC (INCU-line, VWR) for truncated and isoforms of Atx-3. The same procedure 
was used for the expression of NBs with the only exception being the use of LB media 
instead. 
  
 
Expression of Ataxin-3 Variants 
The bacterial film formed ON in the agar plate was collected with a sterile 
incubation loop, inoculated on 500 mL LB-ON medium supplemented with 100 mg/L 
ampicillin and 0.4 % (w/v) glucose and grown at 37 ºC, 180 rpm until the OD600 0.6-0.8. 
The culture was then cooled to 30 °C and protein expression induced with 300 mM 
NaCl. After 3 hours of expression, the cells were harvested by centrifugation  
(Avanti J-26 XP - Rotor J-LITE JLA 8.1000, Beckman-Coulter), resuspended in Atx-3 
lysis buffer and frozen at -20 ºC. 
 
 
Nanobody Expression 
The bacterial film formed overnight on the agar plate collected and inoculated 
on 500 mL of TB medium supplemented with 100 mg/L ampicillin at 37 ºC, 180 rpm 
(Shaker, IKA) until the OD600 0.8–1.0. At this point the NB overexpression was induced 
with isopropyl -D-1-thiogalactopyranoside (IPTG) at a final concentration of 1 mM and 
the medium as further supplemented with ampicillin (100 mg/L). Different expression 
conditions were tested, namely 3 hours at 37 ºC (selected condition), overnight at  
28 ºC and overnight at 25 ºC. After 3 h expression the cells were harvested by 
centrifugation at 4 000 xg, 25 min, 4 ºC (Avanti J-26 XP - Rotor J-LITE JLA 8.1000, 
Beckman-Coulter) resuspended in NB cell lysis buffer and frozen at -20 ºC. 
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Recombinant Protein Purification 
 
Ataxin-3 variants purification 
Before purification, 1 mM of PMSF, 20 g/mL DNase I (from bovine pancreas,  
Sigma-Aldrich) and 1 mM MgCl2 were added to the cells and these were disrupted by 
stirring 1 hour on ice. The supernatant obtained after centrifugation was loaded into a 
pre-equilibrated (with Atx-3 buffer A) Ni2+-charged HisTrap column (GE Healthcare Life 
Sciences) and protein was eluted with a gradient of imidazole (50 mM, 250 mM and 
500 mM). Atx-3 eluted with 250 mM of imidazole was applied into a HiPrep 26/60 
Sephacryl S-200 HR column (GE Healthcare Life Sciences) equilibrated in Atx-3 gel 
filtration buffer and eluted with a flow rate of 2 mL/min. After SDS-PAGE analysis, 
fractions corresponding to pure Atx-3 were pooled and concentrated on Amicon  
Ultra-15 (cut-off 10 kDa) centrifuge filter (Millipore) to 20-30 mg/mL. After 
concentration, the protein was centrifuged for 15 min at 15,000 rpm at 4 ºC (Himac CT 
15 RE, VWR), aliquoted, frozen in liquid nitrogen and stored at -80 ºC. 
  
Nanobody Purification 
Overexpressed cells were thawed and left stirring during one hour in NB cell 
lysis buffer. The soluble fraction was separated from the insoluble fraction by 
centrifugation (14 000rpm, 45 min, 4 ºC (Avanti J-26 XP - Rotor J-LITE JA 25.50, 
Beckman-Coulter)). The supernatant obtained after centrifugation was loaded onto a 
pre-equilibrated (with NB Buffer A) Ni2+-charged HisTrap column (GE Healthcare Life 
Sciences) and NB was eluted with a single elution step containing 300 mM of 
imidazole. Eluted protein was applied to a Hiprep 26/60 Sephacryl S-100 HR column 
(GE – Healthcare Life Science) equilibrated in NB gel filtration buffer and eluted with a 
flow rate of 2 mL/min. After SDS--PAGE analysis, fractions corresponding to pure NB 
were pooled and concentrated on Amicon Ultra-15 (cut-off 3 kDa) centrifuge filter 
(Millipore) to 20-30 mg/mL. After concentration, the protein was centrifuged for 15 min 
at 15,000 rpm at 4 ºC (Himac CT 15 RE, VWR), aliquoted, frozen in liquid nitrogen and 
stored at -80 ºC. 
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SDS-PAGE 
During the expression and purification process (and for other studies) samples 
were collected to verify the protein expression levels and possible contaminants by 
conducting a sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
analysis. The composition of the SDS-PAGE gel is mentioned below. Each gel was run 
at 30 mV.  
 
Table 5: SDS-PAGE preparation. Resolving and Stacking gel preparation  
Resolving Gel (12.5 %) Stacking Gel (4 %) 
2.25 mL H2O 1.78 mL H2O 
2.15 mL 1M Tris pH 8.8 0.71 mL 1M Tris pH 8.8 
2.06 mL 40% acrylamide 0.28 mL 40% acrylamide 
65.2 L 20% SDS 28 L 20% SDS 
65.2 L 10% APS 28 L 10% APS 
6.52 L TEMED 2.8 L TEMED 
 
SDS-PAGE MARKER: Unstained SDS-PAGE protein ladder standards with the 
corresponding molecular weight (Bio-Rad). 
 
Figure 8: Unstained protein marker: unstained precision Plus protein ladder standard with the respective markers 
molecular weight. 
 
Protein Concentration 
Protein concentration was determined by measuring the absorbance at 280 nm 
with a Nanodrop spectrophotometer (Thermo Fisher Scientific) and using the protein 
extinction coefficient determined from the amino acid sequence (values for Atx-3 and 
NBs are displayed in Appendix).  
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Figure 9: Pull-Down experiment scheme 
carried out to select the most promising 
NBs for further studies. First Atx-3 was 
incubated with different NBs for 30 min. After 
that Anti-Atx-3 13Q 1H9 HRP antibody was 
added for 45 min binding to the sepharose 
beads ensuring the pull-down. 
Nanobody Selection 
After the expression and purification process of all NBs that were produced 
against the JD, a screening was made in order to select the most promising ones. With 
this purpose, a pull-down assay was performed using Atx-3 13Q (full length) as bait 
protein followed by a size exclusion chromatography step to confirm the previous 
results, but in this case, using all four Atx-3 variants. 
 
Pull-Down Assay 
To select the Atx-3 interacting NBs a  
pull-down assay was performed.   
0.50 M of Atx-3 13Q was incubated with 
0.50 M of each, previously purified, NB for 30 min 
at 4 ºC in 500 L of interaction buffer (20 mM 
sodium phosphate pH 7.5, 150 mM NaCl,  
5 % glycerol, 2 mM EDTA, 1 mM DTT). Afterwards, 
1 μL of anti-Atx-3 1H9 antibody was added to the 
mix for 45 min at 4 ºC (this antibody recognizes the 
E214-L233 epitope within the UIM1 of Atx-3). 
Subsequently, the mix was added to 20 L of 
protein G Sepharose 4 fast flow beads  
(GE Healthcare Life Sciences) previously washed 
with interaction buffer. 
The protein G Sepharose 4 fast flow beads 
bind to the Fc (fragment crystalliable) region of IgG 
proteins, in this case to anti-Atx-3 1H9 antibody. 
The latter binds to the Atx-3 13Q, which may 
interact with the NB leading to its pull-down. (Protocol scheme in Figure 9). After 
incubation for 1 h at 4 ºC the mixture was centrifuged at 3,000 rpm (Himac CT 15 RE, 
VWR) for 1 min. The supernatant was removed, and the beads were washed with 
interaction buffer (4x) to ensure the removal of any unspecific interaction. Then, 10 L 
of loading buffer was added to beads and the mix was boiled for 10 min, centrifuged at 
15,000 xg for 10 min (Himac CT 15 RE, VWR), and 10 L of each sample was loaded 
into an SDS-PAGE gel along with the appropriate controls. 
 
 
. 
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Size Exclusion Chromatography 
Size Exclusion Chromatography (SEC) was performed to validate the Atx-3 
binding NBs pre-selected in the pull-down assay detailed above. In this assay all four 
variants of Atx-3 (Atx-3 JD, Atx-3 D1, Atx-3 13Q and Atx-3 77Q) were used. 20 M of 
Atx-3 protein was added to 40 M of NB (1:2 ratio).  After 90 min of incubation of the  
Atx-3 isoform with the NB, on ice, the sample was separated in a Superdex 200 
increase 5/150 GL column (GE Healthcare Life Sciences), pre-equilibrated with 
interaction buffer, at a flow rate of 0.3 mL/min. 200 L fractions were collected and 
stored for subsequent SDS-PAGE analysis. As control, the isolated proteins were also 
applied to the column. 
 
Complex Characterization (Atx-3:NBs) 
Combining the information obtained in the pull-down assay and in the SEC, four 
distinct NBs were selected for further biophysical and structural characterization. In 
order to map the binding sites of the NBs on Atx-3 four different Atx-3 variants were 
used (Figure 6). 
To characterize the interaction between each isoform and the NBs a set of 
experiments was carried out: Isothermal Titration Calorimetry (ITC), Dynamic Light 
Scattering (DLS), Small Angle X-ray Scattering (SAXS) and Thermal Shift Assay. 
 
Isothermal Titration Calorimetry 
The Isothermal Titration Calorimetry (ITC) technique allows the determination of 
the binding affinity and the thermodynamic parameters of an interaction between two 
molecules. The binding affinity (KD), the stoichiometry of the reaction (n) and 
thermodynamic parameters such as enthalpy (H) and entropic factor (-TS) are 
calculated by measuring the heat released or consumed during the interaction, 
providing a thermodynamic profile. 
The measurements of the interaction between Atx-3 variants and the NBs were 
performed at 20 ºC by using a MicroCal VP-ITC calorimeter (GE Healthcare Life 
Sciences). All proteins were dialyzed twice against 1 L of ITC buffer, first for 4 hours 
and then overnight using a 3 kDa cut-off dialysis membrane (Spectrum). After dialysis, 
the protein was filtered on centrifugal filters 0.22 m (Ultrafree, Millipore) by 
centrifugation for 2 min at 12,000 rpm, 4 ºC (Himac CT 15 RE, VWR) to ensure the 
removal of putative protein aggregates. 
The calorimeter cell sample (1.4 mL) was loaded with approximately 10 M of 
each Atx-3 isoform. The titration assay was carried out by sequential 8 L injection of 
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NB (200 M) with 7 min intervals. All titration assays were performed in triplicate except 
for Atx-3 JD isoform, which were only performed once. 
Titration data were analyzed using the Origin 7.0 program from MicroCal in 
order to obtain a non-linear regression using a single binding site model. The heat 
generated due to dilution of the titrant (NBs) was subtracted with a baseline correction.   
 
Dynamic Light Scattering 
Dynamic Light Scattering (DLS) was used to evaluate changes in the molecular 
size of particles in solutions of isolated Atx-3 variants and Atx-3 complexes with NB01.  
DLS was preceded by the purification of Atx-3:NB01 complex by SEC. First, 
each isoform of Atx-3 (0.24 mM) was incubated with NB01 (0.48 mM), in a ratio of 1:2, 
for 90 min on ice. After that, the complex was loaded into a SEC column (Superdex 
200 increase 5/150 GL, GE Healthcare Life Sciences) pre-equilibrated with interaction 
buffer (20 mM sodium phosphate pH 7.5, 150 mM NaCl, 5% glycerol, 2 mM EDTA,  
1 mM DTT) at a flow rate of 0.3 mL/min. Fractions corresponding to the peak of  
Atx-3:NB01 complex were analyzed by DLS. The measurement was performed in 
triplicates using a Zetasizer Nano ZS (Malvern) in a quartz cuvette at 20 ºC with a 
count rate of 390.1 kcps. DLS results were visualized using the Zetasizer software 
7.11. 
 
Small Angle X-ray Scattering 
Size Exclusion Chromatography in line with Small Angle X-ray Scattering  
(SEC-SAXS) was applied to study differences in the shape of Atx-3 13Q:NB01 complex 
in solution. SEC-SAXS data were collected at the BM29 BioSAXS beamline in the 
European Synchrotron Radiation Facility (ESRF, Grenoble) at a wavelength of 
0.9919 Å. 
100 L samples of Atx-3 13Q at 10 mg/mL, NB01 at 10 mg/mL, and complexes 
of 10 mg/mL of Atx-3 13Q incubated with different molar ratios of NB01 (1:1 and 1:2) 
were loaded onto gel filtration chromatography column (Yarra SEC 3 m SEC-3000) 
equilibrated with 20 mM sodium phosphate pH 7.2, 150 mM NaCl, 5% glycerol,  
2 mM EDTA, 1 mM DTT buffer, and eluted at a flow rate of 0.2 mL/min. The eluted 
protein was redirected to the sample flow path for immediate SAXS data collection. 
2500 frames (one per second) were collected at 10 ºC using 1M PILATUS detector 
over a scattering vector (q = (4π sinθ)/λ, where 2θ is the scattering angle) range up to 
0.5 Å-1, which corresponds to a sample-detector distance of 2.867 m. No radiation 
damage was detected. Data collection and treatment was performed by lab colleague 
Dr. José Manso. 
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Baseline subtraction was performed using the solution scattering right before 
the peak elution. Only the frames presenting protein were used for the subsequent data 
treatment. This selection was performed manually and merged to a single averaged 
frame. 
Data was processed and analyzed with the ATSAS 2.8 package138. Pair- 
-distance distribution function, P(r), was calculated with GNOM139. Ab initio shape 
reconstructions were calculated with the program DAMMIF140; fifteen independent 
reconstructions were superimposed, averaged, and filtered with DAMAVER141. 
Scattering profile of atomic structure was calculated with CRYSOL142. SAXS-based 
rigid body modeling of complexes with one or several of lack fragments with CORAL143.  
The 3D atomic structure for the SAXS-based rigid body modeling are the 
presenting ones: JD PDB accession 1yzb, UIM PDB accession 2hlz and PolyQ tract 
PDB accession 4wth and NB structure PDB accession 1I3V. 
 
Thermal Shift Assay 
The Thermal Shift Assay is a temperature based assay designed to study 
protein stability. An increase in temperature triggers the denaturation of the protein. 
During this step, a fluorophore (SYPRO ORANGE (Invitrogen)) may bind to the 
hydrophobic regions of the protein that are now accessible enhancing the fluorescence 
signal. The thermal shift assay was performed for each Atx-3 isoform in the presence 
of the NBs with the highest affinity (NB01 and NB02) to study their impact on the 
thermostability of Atx-3 isoforms and its isolated domains. For each condition, a final 
concentration of 0.3 mg/mL of Atx-3 isoform incubated with NBs (NB01 and NB02) in a 
ratio of 1:5. The experiment was performed in triplicate.  
A final concentration of 10x SYPRO ORANGE dye was used (comparing to the 
stock solution 5000x). The temperature was increased from 25 ºC to 95 ºC in 0.5 ºC 
increments and the fluorescence was measured using a qPCR iQ5 (Biorad) and a Cy3 
filter setup. 
 
Complex Crystallization 
Using the same approach as the one used for the purification of isolated  
Atx-3:NB complexes for DLS analysis, Atx-3 D1:NB complexes were purified by SEC in 
crystallization buffer (20 mM HEPES, 150 mM NaCl, 5% glycerol, 2 mM EDTA and  
1 mM DTT). Fractions corresponding to complex peak were concentrated in an Amicon  
Ultra-15 (cut-off 3 kDa) centrifuge filter (Millipore) to a final concentration of 28 mg/mL 
and centrifuged during 15 min, 4 ºC at 15 000 rpm (Himac CT 15 RE, VWR). 
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The following commercial screens were used in initial crystallization tests: 
ProPlex, JCSG, MIDAS, PACT premier, Morpheus, SG1, PGA screen (Molecular 
Dimensions), Index, PEG/ION, Crystal Screen 1 and 2 (Hampton Research). The drops 
were setup using a crystallization robot Oryx 4 (Douglas Instruments). Two conditions 
were tested in the same crystallization plate: 0.1 L complex drops at a concentration 
of 28 mg/mL were added to 0.1 L of reservoir crystallization solution and a second 
condition in which 0.2 L of complex were added to 0.1 L of reservoir crystallization 
solution in sitting drop plates with 96 wells (SWISSCI, Scientific Innovation) with 50 L 
of reservoir volume. The plate was stored at 20 ºC. 
Scale-up of promising conditions were as well attempted, the precipitant 
concentration was varied from 20 %, 22.5 %, 25 %, 27.5 % to 30 % and the pH of the 
0.1 M Tris buffer varied between 8.3, 8.5, 8.7 and 9.0. Drops consisted on two different 
protein:precipitant ratios: 1 L 28 mg/mL Atx-3 D1:NB01 complex with 1 L of 
precipitant and 1.5 L of 28 mg/mL complex with 0.75 L of reservoir solution in  
24 wells sitting drop plates with 300 L of reservoir volume. The crystallization plates 
were stored at 20 ºC. 
 
Modulation of Ataxin-3 aggregation by Nanobodies 
To study the effect of the selected NB in Atx-3 aggregation, sequential 
techniques were used. First, a Thioflavin T (ThT) aggregation assay was performed 
followed by a Filter Retardation Assay, Dot-blot with amyloid-specific antibodies and 
Transmission Electron Microscopy (TEM).  
 
Thioflavin T Aggregation Assay  
To analyze the effect of the selected NBs in Atx-3 amyloid formation an 
aggregation assay was performed using ThT. This compound is a 
benzothiazole salt that enhances its fluorescence upon binding to -strands due to the 
rotational restriction of the central C–C bond. The binding occurs between side chains 
along the length of amyloid-like fibrils that are formed along the aggregation process. 
However, despite its regular application in aggregation studies, this method has 
some limitations due to the formation of intermediate species that do not bind to ThT144 
and also due to other compounds, such as aggregation modulators, that may be 
present in solution and block the binding of ThT, decreasing the signal.145 The typical 
profile of a ThT aggregation curve encompasses 3 distinct and sequential steps: the 
lag-phase, the elongation phase and the stationary phase. During the lag-phase the 
fluorophore does not report the formation of oligomeric species/protofibrils but the first 
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steps of aggregation are already occurring (concentration below the detection limit), 
leading to the formation of dimers and/or oligomers. After that, during the elongation 
phase, exponential increase in ThT fluorescence signal corresponds to the elongation 
of the oligomeric species into Atx-3 protofibrils/fibrils. The aggregation endpoint is the 
stationary phase in which an equilibrium in the fibrils amount occurs and the signal 
stabilizes. 
 Aliquots of purified Atx-3 variants were thawed on ice and centrifuged at 
15 000 rpm (Himac CT 15 RE, VWR) during 15 min at 4 ºC to remove all precipitated 
protein. Protein was loaded into a Superdex 200 increase 5/150 GL (GE Healthcare 
Life Sciences) equilibrated in aggregation buffer (20 mM sodium phosphate pH 7.5, 
150 mM NaCl, 1 mM DTT). Resulting fractions were kept on ice and the protein 
concentration was determined. After that, the protein was filtered using a centrifugal 
filter 0.22 m (Ultrafree, Millipore) to remove all possible aggregates before the ThT 
experiment.  
Atx-3 variants were diluted to a final concentration of 5 M and NBs were added 
at a final ratio of 1:1 (5 M), 1:2 (10 M), 1:5 (25 M) and 1:10 (50 M). A ThT stock 
(SIGMA Aldrich) solution was added at a final concentration of 100 M. After a gentle 
mix, 50 L of each sample was loaded into Thermowell 96-Well Polycarbonate PCR 
Microplates (Costar) in 3 independent replicates for each condition. The microplate was 
centrifuged (Sorvall ST 40, ThermoFischer Scientific) at 1 200 rpm during 2 min. After 
that, 20 L of parafilm oil (Molecular Dimensions) was added to each well to prevent 
sample evaporation. The plate was placed in FluoDia T70 microplate fluorimeter 
(Photon Technology International) previously heated at 37 ºC, with excitation and 
emission wavelength of 400 nm and 480 nm, respectively. Measurements were 
collected every 30 min and each cycle were preceded by a short orbital agitation. 
 
Filter Retardation Assay 
The first step in Atx-3 aggregation is independent of the polyQ tail and is 
controlled by the aggregation-prone region located within the globular JD. After the 
start of aggregation polyQ tails from different Atx-3 molecules, when expanded, can 
interact completing the second step of aggregation. These interactions between polyQ 
regions are mediated by hydrogen bonds leading to the self-assembly of β–sheets and 
the formation of long and straight mature amyloid fibres that are not disassembled by 
treatment with SDS. When the polyQ region is not expanded, the second step does not 
occur.  
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In the ThT experiment endpoint, 
the microplate was removed from the 
fluorimeter and 5 L of each sample 
was boiled during 5 min in 200 L of 
TBS buffer (50 mM Tris-HCl pH 7.5 and 
150 mM NaCl) with 2% SDS and without 
SDS. After boiling, the mixture was 
loaded into a vacuous system (BioDot 
SF – BIORAD) previously prepared. 
First, two filter papers (BioDot SF – 
BIORAD) were soaked in TBS buffer as 
well as a cellulose acetate membrane, 
pore size 0.2 m (GE Healthcare Life 
Sciences). 
The cellulose acetate 
membrane was placed on top of filter 
paper and the latter was placed in the 
vacuum system (system assembly in 
Figure 10). The vacuum system was 
closed, and the samples were loaded 
into the manifold wells. Samples with 
and without SDS treatment, were 
filtered through the membrane by 
applying vacuum without allowing the membrane to dry. After that, the membrane was 
washed with TBS with 0.1 % SDS (in the samples without SDS treatment) and with 2 % 
SDS (in the samples with SDS treatment). The membrane was blocked with 5 % milk in 
TBS-T buffer (50 mM Tris pH 7.5; 150 mM NaCl and 0.1% Tween 20) during 1 h at 
room temperature. The membrane was incubated with primary antibody anti-Atx-3 1H9 
(1:1000) (Millipore) overnight at 4 ºC followed by the secondary antibody anti-mouse 
(Sigma-Aldrich) (1:10 000) for 2 h at room temperature. The membrane was developed 
using ECL reagent (GE Healthcare Life Sciences).   
  
Dot-blot 
Samples from the ThT aggregation assay were also used to perform a dot-blot 
assay to compare the Atx-3 oligomeric intermediary species present at the endpoint 
aggregation in the absence and in the presence of NB. In this study, the 2 L of each 
sample was loaded into a nitrocellulose membrane (BIORAD) through circular 
Figure 10: Filter Retardation Assay experiment 
representation. The experiment samples were removed 
from the aggregation plate and treated with and without SDS 
and loaded to the vacuous system with a cellulose acetate 
membrane placed on top of filter paper. Without SDS 
treatment, if the fibers are retained in the membrane it shows 
that the sample in study have insoluble fibers and it there not 
the fibers are soluble. With the SDS-treatment if the fibers 
retain in the membrane it is an evidence that we are 
examining mature fibers if not we are studying non-mature 
fibers.    
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templates. The membrane was then blocked with 5 % BSA. The membrane was 
successively incubated with the following antibodies: Antibody anti-Atx-3 1H9 (ON at 
4 ºC), Antibody Anti-OC (ON at 4 ºC) and Antibody Anti-A11 (1h at RT). Between each 
immunoblot the membrane was stripped using Restore Western Bolt Stripping Buffer 
(Thermo Fisher Scientific). Information about the primary antibodies and their 
secondary antibodies is detailed in Table 4. 
 
Transmission Electron Microscopy 
To analyze the morphology of the aggregates/protofibrils/fibrils present at the 
endpoint of ThT assay, negative-stain transmission electron microscopy (TEM) using 
carbon-coated 200 mesh nickel grids (FCF300-NI, Electron Microscopy Science) was 
executed. The endpoint samples were diluted in to a final concentration of 2.5 M of  
Atx-3 with milliQ water. 5 L of the diluted sample was placed and absorbed by the 
grids (Electron Microscopy Science) during 2 min. After that, 2 L of 2 % (w/v) uranyl 
acetate (ANAME) was loaded in the grid for 15 sec for negative-staining. The images 
were acquired at a magnification of 80,000–100,000x using an electron microscope 
JEM-1400 (JEOL) at an accelerating voltage of 80 kV at IBMC, Porto, Portugal. 
 
Time course analysis of Atx-3 self-assembly 
To study soluble species involved in the early events of the aggregation 
pathway an oligomerization time course analysis was performed using SEC. In 
addition, a DLS experiment was performed to study the molecular distribution of the 
sample along the aggregation.  
 
Size Exclusion Chromatography  
To monitor the effect of NB01 and NB05 in the soluble species formed during  
Atx-3 13Q and Atx-3 77Q isoforms aggregation a time course analysis using SEC was 
performed. Along the aggregation process, samples were loaded in a Superdex 200 
increase 5/150 GL (GE Healthcare Life Sciences).  
Using the protocol previously described, the protein was thawed, centrifuged 
and injected in a Superdex 200 increase 5/150 GL (GE Healthcare Life Sciences) to 
remove some intermediary species and to remove the glycerol that was present in the 
Atx-3 buffer. After elution, protein concentration was determined, and the protein was 
diluted to a final concentration of 5 M in 700 L. NB01 (for Atx-3 13Q and 77Q) and 
NB05 (for Atx-3 77Q) was added to a final concentration of 10 M and 50 M, 
respectively. The samples, Atx-3 13Q 5 M (control), Atx-3 13Q:NB01 (1:2),  
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Atx-3 77Q 5 M (control), Atx-3 77Q:NB01 (1:2), Atx-3 77Q:NB05 (1:10), NB01  
(10 M) and NB05 (50 M) were incubated at 37 ºC without shaking. At different time 
points, 50 L aliquots were collected, filtered in a centrifugal filter 0.22 m (Ultrafree, 
Millipore) and injected into a Superdex 200 increase 5/150 GL (GE Healthcare Life 
Sciences). 
To monitor the assay and to select the proper times for the chromatography 
step a ThT assay under the same experimental conditions was also performed 
simultaneously. 
 
Dynamic Light Scattering 
To study the effect of NB01 in the average size distribution of species during the 
Atx-3 13Q self-assembly an aggregation assay was made using DLS.  Measurement 
were performed using an ALV/DLS/SLS-5000F, SP-86 goniometer system  
(ALV-GmbH) equipped with a CW diode-pumped Nd:YAG solid-state Compass-DPSS 
laser with a symmetrizer (Coherent Inc). The laser operated at 488 nm with an output 
power of 400 mW. The intensity scale was calibrated against scattering from toluene.  
The samples, 700 L of 5 M Atx-3 13Q and Atx-3 13Q:NB01 (1:2), previously 
centrifuged, repurified in aggregation buffer and filtrated in a centrifugal filter 0.22 m 
(Ultrafree, Millipore) were incubated in a DLS glass cuvette at 37 ºC and scattering was 
periodically at a 90º angle to the incident beam. Hydrodynamic radii of the particles in 
solution were estimated from the diffusion coefficient obtained from COMTIN3 analysis 
of the auto-correlation function of scattered light intensity. Data collection and treatment 
was performed by lab colleague Dr. Pedro Martins. 
 
  
FCUP/ICBAS/i3S 
Molecular tools to tackle Ataxin-3 aggregation in Machado-Joseph disease 
- 29 - 
 
Results and Discussion  
 
Recombinant Protein Purification 
Purification of Ataxin-3 isoforms and truncated variants 
The four Atx-3 variants used in this study (Josephin Domain (JD), D1, full-length 
13Q and full-length expanded 77Q) (Figure 6) were expressed according to the 
protocol previously described in methods. After expression, the cells were lysate and 
the supernatant was loaded onto a pre-equilibrated Ni2+- charged Histrap and the 
protein was eluted with a gradient of imidazole (Figure 11A, green line). Atx-3 eluted 
with 50 % of imidazole (250 mM) was applied to a second purification step by size 
exclusion chromatography (SEC) (Figure 11B, 11D, 11F and 11H) to ensure the 
removal of any contaminants and possible aggregates or intermediate protein states 
that are formed during the expression and purification process, thereby enriching the 
monomeric form.  
The Atx-3 variants have different elution volumes due to their different 
molecular weights (Figure 11B, 11D, 11F and 11H). During the purification process 
aliquots were collected and loaded in a SDS-PAGE to confirm the purity of the final 
protein in each step of the purification process (Figure 11C, 11E, 11G and 11I). The 
protein yield varies according to the Atx-3 isoform (Figure 11J). 
SDS-PAGE gels demonstrate that throughout the purification process the 
presence of contaminants is reduced but in some cases, after the final step, some 
contaminants are still present. Analyzing the SEC profile (Figure 11B, 11D, 11F and 
11H), it is noticed that protein aggregates are formed during the expression and 
purification process, particularly in the full-length proteins containing the polyQ tract 
that increases the protein aggregation tendency. 
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Figure 11: Purification of Atx-3 variants. A) Representative of a Ni
2+
- charged Histrap elution profile with two steps, 
first with lower imidazole concentration (50 mM, 10% buffer B) and then with an increased concentration of imidazole 
(250 mM, 50% buffer B) (green line). Protein elution was detected by monitoring the absorbance at 280 nm (left axis). 
Size exclusion chromatography profile of B) Atx-3 JD (green), D) Atx-3 D1 (orange), F) Atx-3 13Q (grey) and H)  
Atx-3 77Q (red). The selected fractions were injected into a size exclusion chromatography column where the protein 
elution could be observed by following monitoring the absorbance at 280 nm. SDS-PAGE was used to monitor the 
sample purity throughout the purification process for each variant: C) Atx-3 JD, E) Atx-3 D1, G) Atx-3 13Q and I) Atx-3 
77. J) Summary table of molecular weight, elution fractions selected in SEC and pooled together for further assays, 
elution volume of the main peak and expression yield for each Atx-3 variant. 
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Small-Scale expression and purification of the Nanobodies 
 Following expression and purification of Atx-3 constructs the selection of the 
most promising NBs for the forthcoming studies was also required, starting with small- 
-scale expression (500 mL culture) and purification steps. First, three distinct 
expression conditions were tested in TB medium in which the temperature and the 
induction time were varied: 4 hours at 37 ºC, overnight (ON) at 28 ºC and finally ON at 
25 ºC (Figure 12A). The presence of a secretion signal within the NBs sequence 
mediates the export of the protein to the periplasmic space, allowing the preparation of 
a cell extract by osmotic shock thereby considerably decreasing the amount of 
contaminants present in the soluble fraction. Regarding the expression conditions, no 
major differences in protein expression are visible between the expression conditions 
and the protein in study, in all cases, is present in the soluble fraction. It is further noted 
that before IPTG addition there is no NB expression proving that the system is 
controlled and there is no basal expression. Therefore, the temperature of 37 ºC and 
cell collection 4h after induction was selected for expression of all NBs being studied. 
 
Figure 12: Small-scale expression and purification of NBs. A) Representative SDS-PAGE analysis of expression 
conditions tested for NB05. Cell growth temperatures of 37 ºC, 28 º and 25 ºC were tested, and expression was induced 
with IPTG for 4 hours (37 ºC) or overnight (ON).  Soluble (S) and insoluble (I) fractions were analyzed before and after 
induction of protein expression. B) Representative Ni
2+
- charged Histrap chromatography profile showing a single elution 
step with 100% buffer B (300 mM Imidazole) (green line). C) Size exclusion chromatography. Protein was detected by 
monitoring the absorbance at 280 nm. D) SDS-PAGE analysis of the purification steps (Lysis, Ni
2+
- charged Histrap 
pooled fraction, Flow Through and SEC fractions). 
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After the selection of the best expression condition, the NBs were purified by 
two sequential steps: first with an Ni2+-charged Histrap (Figure 12B) with only one 
elution step (300 mM imidazole) in which the NB-containing fraction was loaded on the 
SEC column (Figure 12C). The purity of the samples was analyzed by SDS-PAGE gel 
(Figure 12D). 
Unfortunately, one of the NBs (NB10) raised against Atx-3 JD did not express in 
the soluble fraction in the preliminary expression screen and consequently it was not 
used for further studies.  
  
 
Nanobody Purification (Large–Scale) 
A large–scale expression and purification was required after the selection of the 
most promising NB (described below). Scale–up to 3L of culture was carried out using 
the same protocol and purification was done as described above:  Ni2+-charged 
Histrap chromatography (Figure 13A) followed by SEC. The four NB that were selected 
for large scale purification (see below) have slightly different elution volumes, which 
result from small differences in their molecular weights and/or additionally from 
possible interactions with the column matrix (Figure 13B, 13D, 13F and 13H). 
Throughout the purification procedure samples were collected and analyzed by SDS- 
-PAGE to verify their purity. It is noted that during the purification the contaminants in 
the total extract are almost totally removed (Figure 13C, 13E, 13G and 13I), but the 
expression yield varies greatly depending on the NB (Figure 13J). 
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Figure 13: NB Purification (large-scale). A) Representative Ni
2+
- charged Histrap elution profile with a purification step 
with 100 % buffer B (300 mM Imidazole) (green line). Protein elution was detected by monitoring the absorbance at 280 
nm (left axis). SEC profile of B) NB03 (brown), D) NB02 (purple), F) NB05 (pink), H) NB01 (grey). Protein presence was 
monitored by measuring the absorbance at 280 nm. The NB-containing fractions were injected into a size exclusion 
chromatography column where the protein elution could be observed by following monitoring the absorbance at 280 nm. 
SDS-PAGE was used to monitor the sample purity throughout the purification process for each variant: C) NB03, E) 
NB02, G) NB05 and I) NB01. J) Summary table of molecular weight, elution fractions selected in SEC and pooled 
together for further assays, elution volume of the main peak and expression yield for each NB.  
 
NB Molecular S100 S100 Yield
nr. Weight (Da) Factions Elution Volume (mL) mg/L of culture
NB03 15091.6 25-28 197
NB02 14499.2 24-27 195
NB05 14080.6 27-30 209
NB01 14155.7 30-34 227
NB purification
3.0 - 6.3 mg/L
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Selection of Atx-3 interacting nanobodies 
 
Pull-Down Assay 
After completing the expression and purification of Atx-3 constructs and all of 
the NBs produced against the JD it was necessary to make a pre-selection of the most 
interesting candidates for future studies. This was achieved with a pull-down assay 
using Atx-3 13Q (full length) variant as bait protein and all 17 NBs (see Figure 14). 
In this assay, sepharose beads coated with protein G were used to bait the 
monoclonal anti-Atx-3-1H9 antibody. Upon incubation of the NBs with the Atx-3 13Q its 
immunoprecipitation with anti-Atx-3-1H9 antibody will capture the specific Atx-3 13Q 
interactors, which will be then detect by SDS-PAGE (schematic representation of the 
protocol in Figure 9). 
Analyzing the results shown in Figure 14A it is perceptible when the sepharose beads 
are incubated with the Anti-Atx-3 1H9 antibody the presence of two bands 
corresponding to the antibody heavy (higher molecular weight) and light chains (low 
molecular weight). When beads are incubated with Atx-3 13Q, the presence of a light 
band is visible, showing that a nonspecific binding occurs between the beads and the 
Atx-3 13Q itself, yet, this will not interfere with the pull-down assay. When Atx-3 13Q is 
incubated with the beads in the presence of the antibody three bands are detected, the 
two antibody related bands and one corresponding to Atx-3 13Q. 
NBs controls were also performed and when NB is incubated with the beads, a  
non-specific interaction is present (low molecular weight band). However, the coating of 
the sepharose beads with the anti-Atx-3 1H9 antibody prevented the binding of NB to 
the beads (Figure 14A).  
Finally, this assay suggests the formation of a complex between Atx-3 13Q and 
NB01 as well as between Atx-3 13Q and NB02, which is demonstrated in the SDS- 
-PAGE gel. Nevertheless, NB03 (Figure 14B) and NB05 (Figure 14A) are not captured 
upon incubation with Atx-3 13Q suggesting that no interaction occurs, at least with this 
variant of Atx-3 and/or in these condition, but which does not exclude the putative 
interaction with other Atx-3 variants, which was further evaluated as detailed below. 
 
FCUP/ICBAS/i3S 
Molecular tools to tackle Ataxin-3 aggregation in Machado-Joseph disease 
- 37 - 
 
 
Figure 14: Pull-Down Assay between Atx-3 13Q and NBs produced against JD. Experimental controls and assay 
results were analyzed by SDS-PAGE. The legend for each lane is displayed above the gel. The NB01 and NB02 
interact Atx-3 13Q, while NB03 and NB05 do not interact with this variant in the conditions tested in the pull-down assay.   
   
As mentioned above, this is a fast way to select some promising interactors of 
Atx-3. Yet, these results must be confirmed by additional experiments, such as a gel 
filtration to exclude the existence of false positives (non-specific interaction) or false 
negatives (NB interaction not detected probably due to blocking of the binding site by 
the antibody or the complex affinity is too low to be detected by SDS-PAGE). 
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Table 6: Summary of the Pull-Down Assay Results in the screen for Atx-3 13Q interacting NBs. ✓  represents a 
positive interaction with Atx-3 13Q; X no interaction detected using this approach * represents the NB that was not 
tested due to its insolubility in the preliminary expression and purification assays. 
Pull-Down Assay 
Atx-3 13Q vs 
NB01 ✓ 
NB02 ✓ 
NB03 X 
NB04 ✓ 
NB05 X 
NB06 ✓ 
NB07 ✓ 
NB08 X 
NB09 X 
NB10 * 
NB11 ✓ 
NB12 X 
NB13 ✓ 
NB14 ✓ 
NB15 ✓ 
NB16 X 
NB17 ✓ 
NB18 ✓ 
 
 
Size Exclusion Chromatography 
 To verify the negative interaction detected for NB03 and NB05 and to validate 
the NBs selected as potential interactors (NB02 and NB01) a SEC was carried out.    
Atx-3 variants (20 M) and each NB (40 M) were incubated (1:2 ratio) and 
loaded into a gel filtration column. Resulting fractions were loaded in an SDS-PAGE to 
confirm the coexistence of both proteins in each peak. Atx-3 and each NB were also 
loaded separately to determine the elution volume of each isolated protein. This assay 
was performed with NB03, NB05, NB02 and NB01 incubated with the four Atx-3 
variants (Atx-3 JD, Atx-3 D1, Atx-3 13Q, Atx-3 77Q). 
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NB03  Based on the pull-down assay NB03 was selected as a non-interactor of  
Atx-3 13Q and the SEC profile confirms this notion (Figure 15). Based on this 
information this NB was used in subsequent assays as a negative control.  
 
NB05  Regarding NB05 (similarly to NB03, NB05 in the pull-down assay was not 
captured suggesting no affinity to Atx-3 13Q), a small shift for a higher molecular 
weight observed in the SEC profile upon incubation with Atx-3 D1 and Atx-3 13Q 
(Figure 16B and 16C), suggesting the formation of a complex. However, no shift was 
observed upon incubation with Atx-3 JD (Figure 16A) and only a slight increase in the 
absorbance of the complex with Atx-3 77Q (Figure 16D).  An explanation for these 
results could be that in the pull-down assay, the antibody Anti-Atx-3 1H9 used against 
Atx-3 13Q may have hindered the interaction interface between NB05 and Atx-3 13Q. 
In the SEC studies, due to the absence of the Anti-Atx-3 antibody, the formation of the 
complex was possible. 
 
NB02  Incubation with JD followed by SEC analysis revealed no evidence of complex 
formation with NB02 (Figure 17A) even though this NB was specifically produced 
against this truncated variant. Nonetheless, upon incubation of Atx-3 D1 with NB02 the 
formation of a complex was observed with a shift of the peak to a lower elution volume, 
corresponding to a higher molecular weight, accompanied by the decrease in the 
absorbance of the peak corresponding to isolated NB02 (Figure 17B). The same result 
was obtained upon incubation with Atx-3 13Q and Atx-3 77Q (Figure 17C and Figure 
17D, respectively) demonstrating that NB02 interacts with Atx-3 D1, Atx-3 13 and  
Atx-3 77Q variants. Additionally, SDS-PAGE gels from the SEC fractions were 
performed and the presence of both NB02 and Atx-3 variants in the fractions peaks 
corresponding to the complexes were confirmed (Figure 17). These results confirm the 
pull-down experiment, but more information regarding the complex formation was 
needed.  
 
NB01  Using the same approach, the binding of NB01 to Atx-3 variants was also 
tested. Like the other NBs, NB01 apparently does not interact with Atx-3 JD (Figure 
18A). Still, complex formation between NB01 and Atx-3 D1 (Figure 18B), Atx-3 13Q 
(Figure 18C) or Atx-3 77Q (Figure 18D) variants was observed by SEC and the 
presence of both NB01 and Atx-3 variants in the peaks corresponding to the 
complexes were confirmed by SDS-PAGE. As the NB01 peak disappeared entirely it 
can be hypothesized that this interaction will not occur in a ratio of 1 Atx-3 
(D1/13Q/77Q) to 1 NB01 but may occur in a 1 Atx-3 to 2 NB01 or even in a higher 
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ratio. However, based only on this experiment we cannot make this kind of assumption 
and a further biophysical characterization of the complex was intended next.  
 Regarding all data obtained with the SEC and the pull-down experiments it was 
possible to confirm the interaction between NB02 and NB01 with all Atx-3 constructs 
except for Atx-3 JD (even though the NBs were specifically produced against this 
domain). A possibility for this lack of interaction may be the NB’s ability to recognize 
only a specific conformation of Atx-3 JD. This specific conformation may be present at 
a higher frequency in the longest variants such as Atx-3 D1 (with the UIM1-2) or the 
full-length Atx-3 13Q and Atx-3 77Q. So, the interaction of the JD to these 
conformational NBs could be transient or too low to be detected by SEC, contrarily to 
what happened with the longer Atx-3 variants.  
NB03, as previously shown by the pull-down assay and confirming with SEC, 
does not interact with Atx-3. Therefore, it will be used as a negative control for the 
subsequent experiments. NB05, which had been previously considered a negative 
control with no Atx-3 13Q interaction, is now a promising tool for future studies. 
Nevertheless, complementary biochemical assays are necessary to accomplish a more 
complete complex characterization with these four selected NBs and Atx-3 constructs. 
 
 
NB03 
 
Figure 15: Size Exclusion Chromatography of Atx-3 variants incubated with NB03 profile. A) Atx-3 JD (green 
line), NB03 (brown line) and Atx-3 JD: NB03 complex  (black dots). B) Atx-3 D1 (orange line), NB03 (brown line) and 
Atx-3 D1:NB03 complex (black dots). C) Atx-3 13Q (black line), NB03 (brown) and Atx-3 13Q:NB03 complex (black 
dots). D) Atx-3 77Q (red line), NB03 (brown line) and Atx-3 13Q:NB03 complex (black dots). There is no stable complex, 
both protein bands (Atx-3 variants and NB03) are eluted separatly. 
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NB05 
 
 
Figure 16: Size Exclusion Chromatography of Atx-3 variants incubated with NB05 profile A) Atx-3 JD (green line), 
NB05 (pink line) and Atx-3 JD:NB05 complex  (black dots). B) Atx-3 D1 (orange line), NB05 (pink line) and Atx-3 
D1:NB05 complex (black dots). C) Atx-3 13Q (black line), NB05  (pink line) and Atx-3 13Q:NB05 complex (black dots). 
D) Atx-3 77Q (red line), NB05 (pink line) and Atx-3 13Q:NB05 complex (black dots). Formation of a stable complex in 
(B) Atx-3 D1, (C) Atx-3 13Q and (D) a slight increase Atx-3 77Q shift to higher molecular weight, absorvance increase 
and desapearing of NB05 band. (A) Atx-3 JD no stable complex is formed. In the Atx-3 JD and NB02 the peak were not 
sucessfully separeted. 
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NB02 
 
Figure 17: Size Exclusion Chromatography of Atx-3 variants incubated with NB02 profile. A) Atx-3 JD (green 
line), NB02 (purple) and Atx-3 JD:NB02 complex (black dots). B) Atx-3 D1 (orange lines), NB02 (purple line) and  
Atx-3 D1:NB02 complex (black dots). C) Atx-3 13Q  (black line), NB02 (purple) and Atx-3 13Q:NB02 complex (black 
dots). D) Atx-3 77Q (red line), NB02 (purple line) and Atx-3 13Q:NB02 complex (black dots). Complex elution is evident 
in (B)  Atx-3 D1:NB02, (C) Atx-3 13Q:NB02 and (D) Atx-3 77Q:NB02. There is no stable complex formation between 
Atx-3 JD and NB02. Bellow the chromatographic profiles the SDS-PAGE analysis is shown, demonstrating the presence 
of both proteins in the peak corresponding to the complexes.. In the Atx-3 JD and NB02 the peak were not sucessfully 
separeted. 
FCUP/ICBAS/i3S 
Molecular tools to tackle Ataxin-3 aggregation in Machado-Joseph disease 
- 43 - 
 
NB01 
 
Figure 18: Size Exclusion Chromatography of Atx-3 variants incubated with NB01 profile. A) Atx-3 JD (green 
line), NB01 (blue) and Atx-3 JD:NB01 complex (black dots). B) Atx-3 D1 (orange lines), NB01 (blue line) and  
Atx-3 D1:NB01 complex (black dots). C) Atx-3 13Q  (black line), NB01 (blue) and Atx-3 13Q:NB01 complex (black dots). 
D) Atx-3 77Q (red line), NB01 (blue line) and Atx-3 13Q:NB01 complex (black dots). Complex formation is evident in  
(B) Atx-3 D1:NB01, (C) Atx-3 13Q:NB01 and (D) Atx-3 77Q:NB01. There is no stable complex formation between Atx-3 
JD and NB01. Bellow the chromatographic profiles the SDS-PAGE analysis is shown, demonstrating the presence of 
both proteins in the peak corresponding to the complexes. In the Atx-3 JD and NB01 the peaks were not sucessfully 
separated. 
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Characterization of the Atx-3:Nanobody complexes 
 
Isothermal Titration Calorimetry 
Isothermal Titration Calorimetry (ITC) assay was the technique chosen to 
characterize the nature of the interaction between Atx-3 and each NB. For this, the  
Atx-3 variants used in this work were separately titrated with each NB (in order, NB03, 
05, 02, 01). With this experiment, it was possible to obtain the dissociation constant 
(KD), stoichiometry (n) and thermodynamic parameters (G, H, -TS) of the binding at 
20 ºC. 
 
NB03  Once again no interaction between NB03 and Atx-3 was observed (flat signal, 
Figure 19A), either because i) it does not occur, ii) affinity is so low that it is not 
detected by this experimental condition or iii) this interaction does not generate or 
consume heat, preventing the interaction parameters to be calculated. Nonetheless, 
even if some interaction occurs this NB can still be used as a negative control in the 
following experiments since it cannot be detected. 
 
NB05  It was possible to observe an interaction between NB05 and all the Atx-3 
variants except for Atx-3 JD (Figure 20A). Using this technique, the KD for the 
interactions between NB05 and the Atx-3 variants was determined as 407  32 nM for 
Atx-3 D1, 393  36 nM for Atx-3 13Q and 446  13 nM for Atx-3 77Q (Figure 20B, 20C 
and 20D). The stoichiometry for these interactions is 1:1 demonstrating one Atx-3 
binding site per NB.  Additionally, it was also possible to determine the energy profile of 
the interaction (Figure 20E), in which the enthalpy energy is the component that 
dictates the complex formation, indicating a favorable hydrogen and/or van der Walls 
interactions. 
 
NB02  ITC data regarding NB02 also revealed no binding towards Atx-3 JD  
(Figure 21A) contrasting, once again, with the well-established interaction observed for  
Atx-3 D1 (KD = 1.4 ± 0.3 mM) (Figure 21B) with a stoichiometry of 1:1. The presence of 
the C-terminal region containing the polyQ tract increased the binding affinity of NB02 
towards Atx-3 13Q (Figure 21C) and 77Q isoforms (Figure 21D)  (KD = 428  34 nM 
and 911  54 nM, respectively) interestingly with a stoichiometry of 1:2 for both. With 
this data, it is possible to suggest that Atx-3 D1 only has one interaction site and  
Atx-3 13Q and 77Q have two interaction regions for NB02 and it can be hypothesized 
that this second interaction site is located after the ubiquitin interaction motifs (UIM1-2).  
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Additionally, NB02 presents higher affinity to Atx-3 13Q and Atx-3 77Q than to  
Atx-3 D1, which may be explained by an increase in binding sites. This NB also 
exhibits an interaction for Atx-3 dictated by the enthalpic factor (Figure 21E), indicating 
that no large conformational changes occur during the complex formation, which is 
typical characteristic of this type of interaction (antibody:antigene)146,147. 
 
NB01  Even with ITC it was still not possible to detect an interaction between NB01 
and Atx-3 JD (Figure 22A). However, the binding of NB01 to Atx-3 D1 was in the 
nanomolar range with a KD of 49.4  6.7 nM (Figure 22B). This time, the presence of 
the C-terminal region, containing the polyQ tract, slightly reduced the affinity of the 
NB01 towards Atx-3, namely to the non-expanded isoform Atx-3 13Q  
(KD = 212  9 nM)  (Figure 22C), and Atx-3 77Q (KD = 333  49 nM) (Figure 22D). 
Regarding stoichiometry of interaction all 3 variants have a ratio of 1 Atx-3 molecule 
(D1, 13Q and 77Q) to 2 molecules of NB01 (Figure 22F), which agrees with preliminary 
SEC results. Again, the energetic parameter with the greatest impact was the enthalpic 
factor. 
 
 
Comparing ITC data for all NBs, the NB with the highest affinity for the  
Atx-3 variants is NB01. Stoichiometry of reaction varies between a ratio of 1:1 and 1:2 
(Atx-3 to NB) depending on the NB and on the Atx-3 variant. The energetic parameter 
controlling the complex formation in all samples corresponds to the enthalpic factor, 
indicating the formation of hydrogen and van der Walls interactions between the two 
proteins. This also indicates that no major structural changes are occurring.  
NB03 once again was incapable of presenting any interaction with Atx-3. 
Contrarily, interaction between NB05 and Atx-3 variants was confirmed with an affinity 
even higher than NB02. Still, the stoichiometry duality (in NB01 and NB02) raises the 
question: how can NBs recognize more than one region in Atx-3 protein? In order to 
clarify this, Dynamic Light Scattering (DLS) and Small Angle X-ray Scattering (SAXS) 
were performed. 
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NB03 
 
Figure 19: Thermodynamic profiles of the NB03 interactions with Atx-3 variants analyzed by ITC. A) Atx-3 JD vs 
NB03, B) Atx-3 D1 vs NB03, C) Atx-3 13Q vs NB03, D) Atx-3 77Q:NB03. Measurement of the heat that is released 
during the NB03 injections (cal/seg). E) Absence of parameter values. 
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NB05 
 
Figure 20: Thermodynamic profiles of the NB05 interactions with Atx-3 variants analyzed by ITC. A) Atx-3 JD vs 
NB05, B) Atx-3 D1:NB05, C) Atx-3 13Q:NB05, D) Atx-3 77Q:NB05. Measurement of the heat that is released during the 
NB05 injections (cal/seg) and experimental data fitting using a single binding site model. E) Energetic parameters of 
the complex formation (Atx-3 D1, Atx-3 13Q and Atx-3 77Q) G (blue), H (green) and -TS (red). F) ITC parameter 
values N (molar ratio), KD, H, -TS and G, and error calculation in experiment triplicates. 
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NB02 
 
Figure 21: Thermodynamic profiles of the NB02 interactions with Atx-3 variants analyzed by ITC. A) Atx-3 JD vs 
NB02, B) Atx-3 D1:NB02, C) Atx-3 13Q:NB02, D) Atx-3 77Q:NB02. Measurement of the heat that is released during the 
NB02 injections (cal/seg) and experimental data fitting using a single binding site model. E) Energetic parameters of 
the complex formation (Atx-3 D1, Atx-3 13Q and Atx-3 77Q) G (blue), H (green) and -TS (red). F) ITC parameter 
values N (molar ratio), KD, H, -TS and G, and error calculation in experiment triplicates. 
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NB01 
 
Figure 22: Thermodynamic profiles of the NB01 interactions with Atx-3 variants analyzed by ITC. A) Atx-3 JD vs 
NB01, B) Atx-3 D1:NB01, C) Atx-3 13Q:NB01, D) Atx-3 77Q:NB01. Measurement of the heat that is released during the 
NB01 injections (cal/seg) and experimental data fitting using a single binding site model. E) Energetic parameters of 
the complex formation (Atx-3 D1, Atx-3 13Q and Atx-3 77Q) G (blue), H (green) and -TS (red). F) ITC parameter 
values N (molar ratio), KD, H, -TS and G, and error calculation in experiment triplicates. 
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Dynamic Light Scattering  
ITC data regarding the complexes formed between NB01 (and NB02) and Atx-3 
variants suggested an interaction ratio of 1:2 (1 Atx-3 D1/13Q/77Q molecule for  
2 NB01 molecules). As mentioned before this stoichiometry raises some questions, 
such as: how can a NB recognize two distinct regions of Atx-3, i.e. two epitopes? A 
dynamic light scattering (DLS) assay was performed in order to enlighten this question. 
To proceed to this study Atx-3:NB01 complexes, previously incubated during 
90 min in ice, were purified by SEC (Figure 23A, 23B, 23C) followed by DLS analysis 
with triplicate reading of each condition. Isolated Atx-3 variants and NB01 were also 
analyzed to compare the results.  
Atx-3 is known to be an elongated protein with only a single globular domain 
and the same evidence is obtained by DLS. Thus, based on the protein radius (nm), 
the Zetasizer software over-estimates the molecular weight (MW) (kDa) of Atx-3 when 
compared to the theoretical MW calculated using the amino acidic sequence, since 
Zetasizer considers, for the calculation, that all proteins are globular. (A comparison 
between the theoretical and the measured molecular weight is depicted in Figure 23F).  
DLS data demonstrate that, as expected, NB01 (black dots) has a smaller 
particle size than Atx-3 variants or Atx-3:NB01 complexes (Figure 23D, 23E and 23F). 
However, no major differences are observed between the isolated Atx-3 variants and 
the corresponding complexes. The DLS peak of Atx-3 variants and of the 
corresponding Atx-3:NB01 complexes overlap with a very close (Atx-3 13Q vs 
NB01:Atx-3 13Q, Figure 23E) or even with the same hydrodynamic radius (Atx-3 D1 vs 
NB01:Atx-3 D1, Figure 23D) (Atx-3 77Q vs NB01:Atx-3 77Q, Figure 23F). 
Knowing that the complex is formed (by the SEC purification of the complex), 
but that there is no major change in size (by DLS results) it can be assumed that the 
binding of 1 or 2 NB01 leads to the formation of a complex that is closer to the 
theoretical values (amino acid sequence), indicating the gain of a more compact 
globular shape in the complex than in the isolated protein. 
 
Contrary to our expectations with this technique, it was not possible to obtain 
any clarification about the complex Atx-3:NB01 stoichiometry as initially proposed. 
However, it was possible to acquire additional information that was also quite 
interesting. The data suggests that the presence NB01 leads to the formation of a 
complex presenting a more compact globular shape, when comparing to the isolated 
Atx-3 protein, which is greatly elongated due to the UIMs regions and the polyQ 
stretch. 
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Figure 23: SEC profile and DLS assay of the complex between NB01 and Atx-3 variants. A) Atx-3 D1 (orange), B) 
Atx-3 13Q (grey) and C) Atx-3 77Q (red) complex formation with NB01 (grey dots) and purifiaction by SEC. There is an 
overlap of Atx-3 variants and Atx-3:NB01 complexes DLS peak indicating similar particle sizes in D) Atx-3 D1 vs NB01, 
E) Atx-3 13Q vs NB01 and F) Atx-3 77Q vs NB01. This result indicates that the complex is more compact and globular 
than the isolated Atx-3 protein. G) Experiment summary, the decreased polydispersity (PdI) in the three complexes may 
sugest that NB01 may be a useful tool to modulate the aggregation process in Atx-3.   
Hydrodynamic Apparent Theoretical MW
Radius (nm) DLS MW (kDa) (kDA)
NB01 2.09 18.9 14.16 0.39
Atx-3 D1 3.25 53.1 32.58 0.23
Atx-3 D1:NB01 3.25 53.1 46.74 0.14
Atx-3 13Q 3.77 75.1 43.58 0.32
Atx-3 13Q:NB01 3.96 84.3 57.74 0.07
Atx-3 77Q 4.16 94.6 51.88 0.38
Atx-3 77Q:NB01 4.16 94.6 66.04 0.13
Protein PdI
DLS
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One interesting information obtain by DLS was the Polydispersity Index (PdI) 
deduced parameter that allows us to estimate the heterogeneity of the particle size 
distribution in the sample. The closer the PdI value is to zero more monodisperse 
(uniform) is the sample. The PdI of the isolated Atx-3 constructs (Atx-3 D1, Atx-3 13Q 
and Atx-3 77Q) demonstrated higher values (0.23, 0.32 and 0.38, respectively) than 
the corresponding complexes with NB01 (0.14, 0.07 and 0.13, respectively) (Figure 
23G). 
Therefore, it appears that NB01 increases the stability of Atx-3 conformation 
avoiding the occurrence of intermediate protein states. This data suggests that NB01 
may be a good candidate and a potential tool for the modulation of Atx-3 aggregation 
and also for its crystallization.  
DLS results were inconclusive regarding the stoichiometry of the complex.  
Small Angle X-ray Scattering (SAXS) was performed to try to clarify this remaining 
question and hopefully to validate the DLS results.     
 
Small Angle X-ray Scattering  
To complement the information obtained by DLS a SEC-SAXS experiment was 
applied to determine the structural factors radius of gyration (Rg) and maximum 
intramolecular distance (Dmax) to acquire more detailed evidence of the size and shape 
of the complex in solution. With this technique, it would be possible to clarify the 
stoichiometry of the complex.   
To guarantee workable results the Atx-3 13Q and the complexes  
(Atx-3 13Q:NB01 (1:1) and Atx-3 13Q:NB01 (1:2)) were injected into a gel filtration 
column and directly measured.  The frames of each experiment (Atx-3 13Q, the  
Atx-3 13Q:NB01 (1:1) and the Atx-3 13Q:NB01 (1:2)) were used to calculate the 
experimental average scattering curve (colored dots, Figure 24A) that was therefore 
used for subsequent analysis. 
The Guinier plot (Figure 24B) of the scattering data may be used to indicate the 
presence of aggregated protein. Regarding Atx-3 13Q this may be a restrictive step 
due to its tendency for amyloid formation. Yet, observing the linearity of the Guinier plot  
of the scattering data (Figure 24B), the sample was monodisperse and without 
aggregates in both isolated protein and complex samples. In addition, the radius of 
gyration (Rg) was estimated to be 38.4 Å, 43.0 Å and 44.1 Å for Atx-3 13Q,  
Atx-3 13Q:NB01 (1:1) and Atx-3 13Q:NB01 (1:2), respectively. By the addition of 
molecules, the center of mass (Rg) also increased. 
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The distance distribution function (Figure 24C), P(r), was calculated and it 
confirmed the elongated conformation of Atx-3 13Q by the presence of a non- 
-symmetric peak (green line, Figure 24C). Also confirming the DLS results, the NB 
presence at a ratio of 1:1 (pink line, Figure 24C) and, more evident at a ratio of 1:2 
(orange line, Figure 24C), alters the complex to more globular state. This statement is 
supported by the transition from an elongated curve of Atx-3 13Q (green line,  
Figure 24C) to a bell-shape curve of 1:1 and 1:2 for the complexes (pink and orange 
line, Figure 24C). Furthermore, the Dmax of Atx-3 13Q and the complexes is 
approximately the same with 185 Å indicating that the Atx-3 13Q length is in fact the 
longest part of the complex. 
Averaged molecular envelopes of fifteen ab initio independent models were 
generated to reconstruct the shape of Atx-3 13Q and the complexes (grey shape in 
Figure 24D). A value of normalized spatial discrepancy (NDS) below indicates low 
variability between the models. 
Atx-3 13Q and the complex models were generated from the atomic structures 
of several known domains (PDB accession: JD (1yzb), UIM (2hlz), and C-terminal 
(4wth) and NB (1I3V)) and were fitted into the molecular reconstructions showing an 
excellent agreement with the experimental scattering curves (black lines, Figure 24A). 
The best adjusts for the Atx-3 13Q domains complexes with the NB (PBD: 1I3V) are 
represented in Figure 24D. The envelope of Atx-3 13Q control (1) is represented with 
the consecutives domains: Josephin domain (blue), UIM (orange) and C-terminal (red). 
In the complex ratio of 1:1 (2) an additional globular shape is visible corresponding to 
the presence of NB01. Finally, in the ratio of 1:2 (3) a second globular shape is found 
corresponding to the second NB.  
 
With this result, the presence of 2 molecules of NB per 1 molecule of  
Atx-3 13Q is evident. Yet, not all questions were elucidated, it seems that the 
interaction region between the NB01 with the Atx-3 13Q is very close to the JD but it 
cannot be confirmed if in fact this interaction is established in this region. Furthermore, 
the complex fitting with the atomic structure of the Atx-3 13Q and the 2 molecules of 
NB01 is not totally clear whether both NB bind to Atx-3 at two distinct sites or if one of 
the NB is only binding to the other, and not to Atx-3. 
To try to clarify these remaining questions a last attempt was made: 
crystallization trials of the complex between NB01/NB02 (the binding of two of these 
NB per Atx-3 was determined by ITC) with Atx-3.  
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Figure 24: Small angle X-ray scattering coupled to a SEC column (SEC-SAXS) experiment for Atx-3 13Q:NB01 
complex. A) Experimental average scattering curves (color dots) with the respective legend above and the fitting of ab 
initio reconstruction in black lines. Atx-3 13Q (green), Atx-3 13Q:NB01 (1:1) (pink) and Atx-3 13Q:NB01 (1:2) (orange). 
B) Guinier plot of the scattering curve presenting a monodispersed sample (3 experiments) and calculation of Rg with 
44.1 A, 43.0 A and 38.4 A for Atx-3 13Q (green), Atx-3 13Q:NB01 (1:1) (pink) and Atx-3 13Q:NB01 (1:2) (orange), 
respectively. C) Distance distribution function with Atx-3 13Q (green line) presenting an elongated profile. The presence 
of NB01 turns the complex more globular (pink and orange lines). Determination of maximum distance of Atx-3 13Q and 
both complexes with 185 A. D) Ab initio shape reconstruction (grey) of (1) Atx-3 13Q and complexes (2) 1:1 and (3) 1:2. 
The atomic structures (PDB accession: JD (1yzb) (blue), UIM (2hlz) (orange), and C-terminal (4wth (red) and NB (1I3V) 
(green)) were adjusted into the molecules shape with CORAL. NSD demonstrate the molecules flexibility in solution.   
 
 
Thermal Shift Assay (Sypro Orange) 
One of the goals for the study of Atx-3 binding NBs was to use them as a 
crystallization chaperones to stabilize the monomeric Atx-3 protein, facilitate the 
formation of Atx-3 crystals and subsequently determine its three-dimensional structure. 
To detect if any of the selected NB (with a molar ratio of 1:2) are able to stabilize Atx-3, 
a Thermal Shift Assay was performed with NB01 and NB02. 
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Figure 25: Thermal Shift Assay with Atx-3 variants and NB01 or NB02. Atx-3 constructs were incubated with NB01 
or NB02 to analyze differences in the melting temperatures by measuring the emission of Sypro Orange fluorophore 
with temperature (result derivative). A) Atx-3 JD (green line), Atx-3 JD with NB01 (blue line), NB01 control (blue dots), 
Atx-3 JD with NB02 (purple line) and NB02 (purple dots). B) Atx-3 D1 domain (orange line), Atx-3 D1 with NB01 (blue 
line), NB01 control (blue dots), Atx-3 D1 with NB02 (purple line) and NB02 (purple dots). C) Atx-3 13Q domain (black 
line), Atx-3 13Q with NB01 (blue line), NB01 control (blue dots), Atx-3 13Q with NB02 (purple line) and NB02 (purple 
dots). D) Atx-3 77Q domain (red line), Atx-3 77Q with NB01 (blue line), NB01 control (blue dots), Atx-3 13Q with NB02 
(purple line) and NB02 (purple dots). E) Melting temperature summary. 
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The thermal shift assay quantifies the protein stability by monitoring its 
denaturation temperature. A good ligand/chaperone for crystallization may increase the 
protein thermal stability and consequently increase the protein denaturation 
temperature. SYPRO Orange is a fluorophore that binds, nonspecifically, to 
hydrophobic surfaces. With the protein denaturation more hydrophobic surfaces are 
exposed increasing the dye binding and enhancing its fluorescence. The melting 
temperature (TM) is easily determined by plotting the first derivate of the raw data and 
finding its minimum. 
Using this method, small differences were detected but no great evidence of an 
induced stabilization of Atx-3 by the NBs was observed (Figure 25).  
 
Complex Crystallization  
Even thought it was not possible to obtain relevant data from the thermal shift 
assay, crystallization trials of Atx-3:NB complexes were performed using commercial 
crystallography screening kits and a Oryx4 Crystallization robot. 
Different kits and protein-to-precipitant ratios were tested as described in 
Methods. Crystals were obtained in several crystallization conditions. However, most of 
the crystals proved to be salt crystals. Nonetheless, in a condition of the crystallization 
screen Index HT (Hampton Research) (25% PEG 3,350 and 0.1M Tris pH 8.5)  
Atx-3 D1:NB01 complex crystals were obtained (Figure 26). 
 
 
Figure 26: Crystal of Atx-3 D1 variant with NB01.  Crystals of Atx-3 D1 domain complexed NB01 at 28 mg/mL; 
Condition: 25% PEG 3,350 and 0.1M Tris pH 8.5, 0.2L of protein and 0.1 L of crystallization buffer in sitting drop 
plate. 
 
With the aim to obtain larger crystals a scale-up process was tried by fine tuning 
around the buffer pH and precipitant concentration. Efforts are still currently being 
made to reproduce these crystallization conditions. 
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Nanobodies as Modulators of Atx-3 Aggregation 
Before each aggregation assay, separately Atx-3 variant were repurifed to 
exchange buffer to aggregation buffer (without glycerol, which delays aggregation) and 
to remove possible Atx-3 aggregates and intermediate oligomeric species in solution 
formed during the freezing and thawing processes (Figure 27). 
 
Figure 27: Repurification of Atx-3 variants by size exclusion chromatography to remove possible protein 
aggregates and glycerol from the buffer. Protein elution volumes (mL) monitored by absorbance measurement at 
280 nm. The elution fractions are represented in dotted lines. From the lowest to the highest elution volume are the  
Atx-3 77Q (red line), Atx-3 13Q (black line), Atx-3 D1 (orange line) and Atx-3 JD (green line) variants. 
 
The NBs previously characterized (NB03, 02, 05, 01) were incubated with Atx-3 
variants to study their affect in the aggregation. The following techniques were used as 
complementary procedures to fully characterize the details of Atx-3 aggregation in the 
presence of these NBs.  
The impact of the incubation of the NBs with Atx-3 variants was monitored using 
a ThT fluorescence assay. This technique allows the detection of differences in the lag 
phase upon incubation with NBs and to study changes in the elongation mechanism 
(aggregation curve). At the endpoint of the ThT assay a Filter Retardation Assay was 
used to study changes in the insoluble mature fibers caused by the NBs followed by a 
dot-blot to analyze the presence of toxic species using different antibodies as reporters, 
such as anti-A11 (recognizes toxic oligomers in other amyloid disorders) and Anti-OC 
(for fibril recognition). To study changes in the morphology of the fibrils Transmission 
Electron Microscopy (TEM) visualization of the endpoint samples was performed. 
To directly observe the effect of the most promising NBs (and the most effective 
ratios) in the soluble forms of Atx-3 during the dimerization and oligomerization 
processes a SEC time course assay was used. Additionally, in order to study the 
average size distribution of the species in solution during aggregation DLS was used 
as well. The effect of each NB in Atx-3 aggregation is presented individually.  
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NB03 
NB03  NB03 was previously used as a negative control in the characterization of the 
Atx-3:NB interaction so it was interesting to study the effect of a NB that does not 
present any binding interaction with Atx-3 variants in their aggregation. Observing 
Figure 28 the presence of NB03 surprisingly leads to a delay of aggregation of all Atx-3 
variants. Since there is no binding interaction, this inhibition may be caused by the 
increased number of molecules in solution leading to molecular crowding.  An 
interesting effect is the earlier aggregation start of the highest concentration of NB 
comparing with the lower ones. This result may be explained by a change in sample 
conductivity caused by the NB, facilitating the start of aggregation. However, this is 
only a hypothesis and further experiments must be made to understand this behavior. 
 
 
Figure 28: Modulation of 5 M Atx-3 isoforms aggregation by NB03 visualized by a ThT assay. Each plot displays 
the results of the aggregation assay for each isoform incubated with different ratios of NB03, as well as the negative 
controls (Atx-3 isoform alone). The legend corresponding to each sample is shown above the corresponding graphic. 
The plots presented were obtained by means of triplicates. 
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With the aim of studying the effect of NB03 besides the delay in the Atx-3 
aggregation a Filter Retardation Assay was used to observe its effect in the fibril 
species present at the ThT experiment endpoint. 
Atx-3 JD formed soluble species in the experiment endpoint (aggregates are 
mostly soluble/small than the membrane cut-off (0.2 m)) since they are not retained in 
the membrane and the insoluble oligomeric species formed by Atx-3 D1, Atx-3 13Q 
and Atx-3 77Q (Figure 29A) are not changed upon incubation with NB03. The same 
information is obtained regarding the protofibrils/fibrils of Atx-3 JD, Atx-3 D1 and Atx-3 
13Q as well as the mature amyloid fibrils of Atx-3 77Q (Figure 29B). 
 
 
Figure 29: Filter Retardation Assay of endpoint samples from ThT aggregation assay of Atx-3 isoforms 
incubated with NB03. A) Filter retardation Assay without SDS-treatment, Atx-3 JD shows soluble oligomeric species 
while Atx-3 D1, Atx-3 13Q and Atx-3 77Q shows insoluble oligomeric species without changes in the presence of NB03. 
B) Filter Retardation Assay with SDS treatment, Atx-3 JD, Atx-3 D1 and Atx-3 13Q exhibit protofibrils/fibrils without 
change with the presence of NB03 and the mature amyloid fibrils of Atx-3 77Q are also not affected by the presence of 
NB03. The signal was obtained by recognition of total protein in the membrane by antibody 1H9. 
 
Furthermore, to study if other toxic species such as oligomers and protofibers 
are formed during the aggregation process, a dot-blot assay was performed. The 
samples absorbed in the membrane were recognized by the anti-OC and anti-A11 
antibodies. In the case of NB03, no major changes were observed (Figure 30).  
 
Overall, the results obtained using NB03 suggest a basal lag phase retardation, 
possibly due to an increase in molecular crowding, since this NB was initially 
demonstrated to be unable to interact directly with Atx-3 constructs. An odd information 
was acquired with the highest concentration of NB03 used (1:10 ratio) which led to a 
decrease of Atx-3 lag phase. Additional ThT assays are needed to prove if this was an 
isolated result or a recurrent effect in the presence of higher concentrations of NBs. No 
changes were detected in the mature fibers of Atx-3 77Q nor in the toxic species 
recognized by Anti-A11 and Anti-OC.   
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Figure 30: Dot-blot Assay of Atx-3 incubated with NB03. The endpoint samples of ThT assay were used in a Dot 
Bolt assay. The membrane was incubated with different antibodies: Antibody 1H9 (that recognizes the total Atx-3 
protein loaded), an anti-OC antibody (that recognizes amyloid fibrils/protofibrils) and an anti-A11 antibody (that 
recognizes toxic oligomers). A) Dot-blot of Atx-3 D1 with NB03 recognition by anti-1H9 and anti-OC. B) Dot Bolt of Atx-3 
13Q with NB03 recognition by anti-1H9 and anti-OC. C) Dot Bolt of Atx-3 77Q with NB03 recognition by anti-1H9, anti-
OC and anti-A11. There are no major changes in the antibody recognition. 
NB02 
NB02 ITC showed that NB02 interacts with Atx-3 D1, Atx-3 13Q and Atx-3 77Q 
(presenting the lowest affinity of all NB tested) without interacting with Atx-3 JD. Still, 
the ThT assay showed that this NB delays aggregation of Atx-3 constructs. This effect 
appears to be dose dependent (the higher the ratio, the higher the effect). However, 
the inhibitory effect on the aggregation saturates at a ratio of 1:5 (Atx-3 to NB02). 
Furthermore, NB02 has a much higher impact in Atx-3 13Q (Figure 31C) and Atx-3 
77Q (Figure 31D) when compared with the truncated variant Atx-3 D1. Other than an 
increased lag-phase, there is no apparent change in the profile of the aggregation 
curve indicating that the elongation proceeds as usual.  
C 
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Figure 31: Modulation of 5 M Atx-3 aggregation by NB02, visualized by a ThT assay. Each plot displays the 
results of the aggregation assay for each variant incubated with different ratios of NB02, as well as the negative controls 
(Atx-3 variant alone). The legend corresponding to each sample is shown above the corresponding graphic. The plots 
presented were obtained by means of triplicates. 
 
Figure 32: Filter Retardation Assay of endpoint samples from ThT aggregation assay of Atx-3 variants in the 
presence of NB02. A) Filter retardation Assay without SDS-treatment, Atx-3 JD show soluble oligomeric specie, while 
Atx-3 D1, Atx-3 13Q and Atx-3 77Q show insoluble oligomeric species, both without changes in the presence of NB02. 
B) Filter Retardation Assay with SDS treatment, Atx-3 JD, Atx-3 D1 and Atx-3 13Q show protofibrils/fibrils without any 
change with the presence of NB02 while the mature amyloid fibrils Atx-3 77Q are affected by the NB02 presence. The 
signal was obtained by recognition by antibody 1H9. 
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In opposition of NB03 results, NB02 presence modulates the amount of 
insoluble amyloid mature fibers of Atx-3 77Q (Figure 32B). As previously stated (see 
Introduction), mature fibers are in fact a final amyloidogenic structure that protects the 
cell from intermediate toxic species. These toxic oligomeric species are now believed 
to be the true cause for the neurodegeneration associated with this disease. It is 
therefore necessary to evaluate if NB02, which prolongs the lag phase, affects the 
abundance of these toxic species. 
The results shown in Figure 33 indicate that the recognition patterns of the  
Anti-OC and Anti-A11 antibodies are quite similar between the control samples and the 
NB incubation.  
 
 
Figure 33: Dot-blot Assay incubated with NB02. The endpoint samples of ThT assay were used in a Dot Bolt 
assay. The membrane was incubated with different antibodies., Antibody 1H9 (that recognizes the total Atx-3 protein 
loaded), an anti-OC antibody (that recognizes amyloid fibrils/protofibrils) and an Anti-A11 antibody (that recognizes toxic 
oligomers). A) Dot-blot of Atx-3 D1 with NB02 recognition by Anti-1H9 and Anti-OC. B) Dot Bolt of Atx-3 13Q with NB02 
recognition by Anti-1H9 and Anti-OC. C) Dot Bolt of Atx-3 77Q with NB02 recognition by Anti-1H9, Anti-OC and Anti-
A11. There are no major changes in the antibody recognition. 
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An interesting aspect of this result was the fact that NB02 alone (control) was 
also recognized by the Atx-3 antibodies (Anti-OC and Anti-A11). Finally, a third 
antibody was also used (1H9) as a load control for the detection of total Atx-3 as a 
positive control and this antibody also recognizes NB02. 
NB05 
NB05 The study of the effect of this NB (which showed the second highest affinity to 
Atx-3) on the aggregation process of Atx-3 consisted on the same steps as the NBs 
described so far. Results show that Atx-3 JD, Atx-3 D1 and Atx-3 13Q (Figure 34A, 
34B and 34C) aggregation is not greatly affected by the presence of NB05 which 
seems to only have a basal effect (similar to the effect showed on the NB03 studies). 
However, taking in account the fact that the aggregation of Atx-3 77Q, the pathological 
variant of Atx-3, was highly affected by NB05 (Figure 34, 3-fold increase in lag phase), 
it can still be considered as a promising tool to modulate the aggregation of this protein.  
 
 
Figure 34: Modulation of 5 M Atx-3 isoforms aggregation by NB05, visualized by a ThT assay. Each plot displays 
the results of the aggregation assay for each isoform incubated with different ratios of NB05, as well as the negative 
controls (Atx-3 isoform alone). The legend corresponding to each sample is shown above the corresponding graphic. 
The plots presented were obtained by means of triplicates. 
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Considering that NB05 showed a small effect on Atx-3 13Q (similar to NB03), 
the ability to selectively delay the aggregation of Atx-3 77Q makes it a promising 
subject in the search for a modulator of Atx-3 aggregation in the pharmacology of the 
disease.   
Analyzing the results of the dot-blot assay for Atx-3:NB05 complexes (Figure 
35), there is also no apparent increase in the production of toxic oligomeric and 
protofibrils forms, when compared to the control samples. The anti-OC and anti-A11 
antibodies recognized the presence of some species, but the signal was not increased 
by the presence of NB05. The study of this NB is an ongoing work so additional 
experiments and validation assays are still needed. 
  
 
Figure 35: Dot-blot Assay of Atx-3 incubated with NB05. The endpoint samples of ThT assay were used in a Dot 
Bolt assay. The membrane was incubated with different antibodies: Antibody 1H9 (that recognizes the total Atx-3 
protein loaded), an anti-OC antibody (that recognizes amyloid fibrils/protofibrils) and an anti-A11 antibody (that 
recognizes toxic oligomers). A) Dot-blot of Atx-3 D1 with NB05 recognition by anti-1H9 and anti-OC. B) Dot Bolt of Atx-3 
13Q with NB05 recognition by anti-1H9 and Anti-OC. C) Dot Bolt of Atx-3 77Q with NB05 recognition by anti-1H9, anti-
OC and anti-A11. There are no major changes in the antibody recognition. 
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The ability of this NB to specifically modulate the aggregation of Atx-3 77Q was 
explored with additional assays to understand the soluble forms that are generated 
during the aggregation both in the presence and absence of NB05.  
 
Size Exclusion Chromatography Time course (Atx-3 77Q:NB05) 
In the first aggregation assay timepoint (0 hours) (Figure 36A) it is visible that  
Atx-3 77Q is mostly monomeric (fraction 7) and then progressively evolves into the 
HMW oligomeric species peak (fraction 4/5). In some points of the Atx-3 77Q 
aggregation pathway (Figure 36G) the presence of intermediary oligomeric species 
(dimers and low molecular weight oligomers in fraction 6) is traceable.  Along the 
amyloid formation process, total Atx-3 77Q absorbance decreases due to sample 
filtration and consequent retention of insoluble fibrils. At 140h (Figure 36H) there are no 
monomeric species of Atx-3 77Q present.  
In the first injection (0 hours) the complex Atx-3 77Q:NB05 (1:10) is composed 
solely by the monomeric fraction (fraction 7). Oligomerization process seems to start at 
the same time for Atx-3 77Q both with and without NB05 (around 40 to 72 hours of 
incubation). Yet, after 92 or 140 hours Atx-3 77Q evolves very quickly into the HMW 
oligomeric species peak (fraction 4/5) while the Atx-3 77Q:NB05 complex seems to 
remain in the monomeric form. Ultimately, in the last injection (166 hours in), Atx-77Q 
alone is already completely aggregated while the Atx-3 77Q:NB01 (1:10) complex is 
still partially in the monomeric form.  
Soluble intermediates are formed in both Atx-3 77Q control and Atx-3:NB05 
complex samples. 
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Figure 36: Modulation of the aggregation of 5M Atx-3 77Q by incubation with NB05 (1:10). Size Exclusion 
Chromatography analysis at different time points indicated by different colors. A) Atx-3 77Q control, B) Complex of   
Atx-3 77Q and NB05 (1:10). Aggregation comparison between Atx-3 77Q and the complex: C) 0 h, D) 24 h, E) 40 h, F) 
72 h, G) 92 h, H) 140 h, I) 166 h. Aggregation is delayed by the presence of NB05. 
MONOMERIC 
HMW INTERMEDIATED SPECIES 
HMW 
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Thus, NB05 presents very promising results for the specific modulation of  
Atx-77Q aggregation without affect the normal isoform (Atx-3 13Q). Still, more 
experiments need to be performed to verify if the soluble intermediary species that are 
prolonged in the NB05 presence increase the cellular toxicity.   
NB01 
NB01  The effect of NB01, the NB with the highest affinity, in the modulation of Atx-3 
variants is presented in Figure 37. Even though no interaction between NB01 and  
Atx-3 JD was observed by SEC and ITC, ThT aggregation assay shows an apparent 
delay in Atx-3 JD aggregation in the presence of NB01 in a molar ratio of 1:1 (grey 
dots) and 1:2 (grey dots and lines) (Figure 37A). Regarding the Atx-3 isoforms to which 
NB01 presented high affinity, a delay in the aggregation lag phase with the same molar 
ratios was also noticed, especially in the full-length isoforms Atx-3 13Q and Atx-3 77Q. 
Between the molar ratio of 1:1 and 1:2 the increase in the lag-phase of 
aggregation appears to be dose dependent. Remarkably, using a molar ratio of 1:2, the 
lag phase of the Atx-3 13Q and Atx-3 77Q is extended twofold comparing to the 
isolated proteins (Figure 37C and 37D). With the molar ratio of Atx-3:NB01 of 1:5 and 
1:10 (dark grey lines), the lag phase is still longer than the control (without NB01) but is 
strangely shorter than for the ratios 1:1 and 1:2, similar to the result displayed with 
NB03.  
Besides the increase in the lag phase period, the curve profile has no other 
apparent change (Figure 37), pointing to the idea that although NB01 delays Atx-3 
primary nucleation it does not affect the elongation process of aggregation just as the 
other NBs (NB02 and NB05).  
Further information was needed before selecting NB01 as a good Atx-3  
anti-aggregation agent. For example, it was necessary to characterize the oligomeric 
species formed throughout the aggregation process in the presence of the NB01. It 
was also necessary to study if besides extending the aggregation lag-phase this NB 
can also prevent the formation of toxic oligomeric species. 
 
As expected, the protofibrils/fibrils formed during the aggregation process of  
Atx-3 JD, D1 and 13Q are non-mature and SDS-sensitive (Figure 38B), due to the 
absence of the polyQ extension. Consequently, they are not retained in the membrane. 
Insoluble aggregates formed by Atx-3 77Q, containing the polyQ extension, proved to 
be mature SDS-resistant amyloid fibrils which are retained in the membrane after SDS 
treatment. Curiously, at higher molar ratios of Atx-3 77Q:NB01 there is an apparent 
modulation of Atx-3 77Q amyloid fibrils maturation by the NB01. At a molar ratio of 
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1:10, the mature fibrils cannot be detected, which indicates that the NB01 affected and 
or significantly delayed their self-assembly. 
Figure 39A and 39B exhibit the recognition of Atx-3 D1 and Atx-3 13Q by the 
Anti-OC antibody in both control samples and samples with different ratios of NB01. At 
the endpoint of Atx-3 D1 aggregation amyloid fibrils/protofibrils are present, which 
appears to be slightly reduced in the presence of NB01, especially at higher molar 
ratios (1:10). The recognition by the antibodies Anti-A11 and Anti-OC to Atx-3 13Q and 
Atx-3 77Q with NBs incubation appears to be identical with and without NB01. The 
immunoblot assay for Atx-3 77Q was repeated with the Anti-A11 antibody (Figure 39C). 
Despite the background, it was possible to detect toxic oligomeric species in Atx-3 77Q 
alone and in the presence of NB01. Finally, a third antibody was also used (1H9) as a 
load control for the detection of Atx-3 and the amount of Atx-3 was similar in all 
samples. 
 
 
 
Figure 37: Modulation of 5 M Atx-3 aggregation by NB01, visualized by a ThT assay. Each plot displays the 
results of the aggregation assay for each isoform incubated with different molar ratios of NB01, as well as the negative 
controls (Atx-3 variants alone). The legend corresponding to each sample is shown above the corresponding graphic. 
The plots presented were obtained by means of triplicates. 
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Figure 38: Filter Retardation Assay of endpoint samples from ThT aggregation assay of Atx-3 variants in the 
presence of NB01. A) Filter retardation Assay without SDS-treatment, Atx-3 JD shows soluble oligomers species, while 
Atx-3 D1, Atx-3 13Q and Atx-3 77Q show insoluble oligomers species, both without changes in the presence of NB01. 
B) Filter Retardation Assay with SDS treatment, Atx-3 JD, Atx-3 D1 and Atx-3 13Q show protofibrils/fibrils without any 
change with the presence of NB01 while the mature amyloid fibrils of Atx-3 77Q are affected by the NB01 presence. The 
samples are identified by 1H9 antibody binding. 
 
Figure 39: Dot-blot assay incubated with NB01. The endpoint samples of ThT assay were used in a Dot-blot 
assay. The membrane was incubated with different antibodies: Antibody 1H9 (that recognizes the total Atx-3 protein 
loaded), an anti-OC antibody (that recognizes fibrils/protofibrils) and an anti-A11 antibody (that recognizes toxic 
oligomers). A) Dot-blot of Atx-3 D1 with NB01 recognition by Anti-1H9 and Anti-OC. B) Dot-blot of Atx-3 13Q with NB01 
recognition by Anti-1H9 and Anti-OC. C) Dot-blot of Atx-3 77Q with NB01 recognition by Anti-1H9, Anti-OC and Anti-
A11. There are no major changes in the antibody recognition patterns. 
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Finally, to analyze the presence of fibers and possible changes in their 
morphology, TEM was performed using different ratios of NB01 and the three Atx-3 
isoforms (see Figure 40). TEM images obtained for Atx-3 D1, with a scale of 100 nm, 
showed a decrease in the number of protofibrils upon addition of NB01, especially in 
the molar ratio 1:5, with no major changes in their morphology.  
A different perception is obtained when visualizing Atx-3 13Q. It seems that the 
presence of NB01 also decreases the amount of protofibrils, but changes their 
morphology: the protofibrils seem to be longer and thicker. 
Regarding Atx-3 77Q, TEM images of this isoform show the presence of mature 
elongated fibrils. When NB01 is added, these fibrils seem to be less frequent and 
shorter, and with a molar ratio of 1:10 it was not possible to visualize them at all. On 
the other hand, it is possible to see that the number of Atx-3 77Q protofibrils is 
increased by the incubation with NB01.  So, it was once again possible to confirm that 
there is indeed an effect on the aggregation of Atx-3 caused by NB01.  
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Figure 40: Transmission Electron microscopy images of Atx-3 with NB01. A) Atx-3 D1 domain with NB01 in a ratio 
of 1:1, 1:2, 1:5 and 1:10. Decrease in the protofibril number with no changes in the fibrils morphology. B) Atx-3 13Q with 
NB01 in a ratio of 1:1, 1:2, 1:5 and 1:10. Decrease in protofibril number and changes in their morphology. C) Atx-3 77Q 
with NB01 in a ratio of 1:1, 1:2, 1:5 and 1:10. Decrease in the number of mature fibrils and increase in amount of 
protofibril structures. 
 
 NB01 increased both Atx-3 13Q and Atx-3 77Q aggregation lag phase and 
decreased the number of mature Atx-3 77Q fibers Atx-3 13Q protofibrils. Yet, there is 
no apparent change in the toxic forms that are recognized by the Anti-A11 antibody. 
This prompted the study of soluble intermediary species that are formed during the 
aggregation process using a SEC time course assay. Two distinct time courses were 
executed: either Atx-3 13Q or Atx-3 77Q incubated with NB01 in a ratio of 1:2 (ratio 
that lead to a higher lag phase). 
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Time course of Atx-3 aggregation:  
Size Exclusion Chromatography (Atx-3 13Q:NB01 complex) 
This assay was used to monitor selectively the soluble species (that have a high 
contribute for Atx-3 toxicity) that are formed during the ThT assay, which showed the 
average behavior of the total species in solution. Atx-3 13Q aggregation kinetic 
analysis is displayed in Figure 41A, where the superimposed colored curves represent 
the chromatographic profiles of the protein samples collected from the aggregation 
assay at different time points. 
In the beginning (0 hours) it is visible that Atx-3 13Q is mostly monomeric (starts 
in fraction 6) but over time a decrease in absorbance and a gradual shift from the 
monomeric peak to the high molecular weight (HMW) oligomeric species peak (fraction 
4) occurs. Simultaneously, the total absorbance of the sample decreases, which can be 
explained by the increasing amount of insoluble aggregated protein retained in the 
eppendorf filter, a step systematically required before analyzing each sample collected 
along the aggregation process. At 19 h of incubation it’s possible to detect a very small 
amount of Atx-3 13Q present in the intermediate fraction (Figure 41D, fractions 5) of 
the chromatogram. These species are in fact intermediate species formed along the 
aggregation process such as dimers and low molecular weight oligomers. After  
72 hours, it is no longer possible to detect the presence of monomeric form or 
intermediate states of the Atx-3 13Q and all the protein is present in the HMW 
oligomeric species fraction. 
Upon addition of NB01 (in a ratio of 1:2) the starting point (0 hours) consists on 
monomeric fractions just like the Atx-3 13Q control (Figure 41C). Along the aggregation 
process (Figure 41D) only a small part of the complex is converted to the HMW 
oligomeric species. At 72 hours, most of the Atx-3 13Q:NB01 complex is still 
monomeric (Figure 41E) while Atx-3 13Q alone is already predominantly found as 
HMW species. Progressively, the fraction corresponding to the HMW oligomeric 
species increases in comparison with the monomeric form (Figure 41G), but in the final 
time point of the aggregation assay (102 hours), low molecular weight species 
corresponding to the monomeric complex are still detected (Figure 41H), something the 
Atx-3 13Q alone does not display. 
Contrary to Atx-3 13Q alone, the complex chromatographic profile (Figure 41G 
and 41H) exhibits a pronounced presence of intermediate oligomeric species  
(fraction 5). These intermediate species may be stabilized by the presence of NB01 or 
may occur in both experiments but are only detectable in the presence of the NB due to 
a delay of the process overall. 
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Thus, with this assay it was possible to confirm that the first steps of 
aggregation are in fact modulated by the presence of NB01, resulting in a deceleration 
of the aggregation process. Moreover, the experiment also demonstrates that NB01 
remains bound to Atx-3 13Q throughout the process (no NB01 peak reappears). Still, it 
is mandatory to carry out a more detailed characterization of the aggregation species 
size distribution during both Atx-3 13Q and Atx-3 13Q:NB01 aggregation to guarantee 
that no additional species with a different molecular weight are formed along the 
process.  
 
 
INTERMEDIATED SPECIES MONOMERIC 
HMW 
FCUP/ICBAS/i3S 
Molecular tools to tackle Ataxin-3 aggregation in Machado-Joseph disease 
- 74 - 
 
 
Figure 41: Modulation of the aggregation of Atx-3 13Q by NB01. SEC analysis at different time points (0, 19, 26, 
72, 90 and 102 h) indicated by different colors. A) Atx-3 13Q control, B) Complex between Atx-3 13Q and NB01 in a 
molar ratio of 1:2. Comparison of the chromatographic profile of the species formed by Atx-3 13Q and the Atx-3:NB01 
complex along the aggregation time-course: C) 0 h, D) 19 h, E) 26 h, F) 72h, G) 90h, H) 102h. The formation of HMW 
species is delayed by the presence of NB01. 
 
Dynamic Light Scattering (DLS) (Atx-3 13Q:NB01) 
A time-resolved Dynamic Light Scattering (DLS) assay using Atx-3 13Q as 
control and Atx-3 13Q:NB01 complex at a ratio of 1:2 was performed to determine the 
particle size distribution in solution through time (Figure 42). In Figure 42A, the 
aggregation of Atx-3 13Q control is shown in full circles and Atx-3 13Q:NB01 complex 
in empty circles. The aggregation process is measured by the increase of scattering 
intensity represented in normalized units (D) along the time of aggregation. By the 
slope of both elongation curves of fibril formation it is possible to observe that the 
aggregation processes such as the fibril elongation, secondary nucleation and 
fragmentation are not affected. Once more, a remarkable inhibition of the formation of 
initial fibrils (primary nucleation) by NBs is demonstrated. 
In the first moment of fibril formation of Atx-3 13Q, the intensity distribution  
(Figure 42B) shows the presence of small oligomers with hydrodynamic radius  
Rh < 10 nm. Some higher molecular weight species with a scattering intensity closer to  
Rh = 100 nm (primary fibers) are also present in the first hours of incubation (Figure 
42B). These bigger species are present in a very low amount, since they were only 
detected by DLS (and not by SEC). These species work as a template for the well- 
-defined peak centered at Rh = 15 nm (Figure 42D and 42F) that is formed during 
amyloid nucleation (secondary fibrils)148. 
A notorious similarity between Atx-3 13Q alone and Atx-3 13Q:NB01 complex is 
displayed since the shape of the size distribution hardly changes (Figure 42B vs 42C, 
42D vs 42E and 42F vs 42G). 
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Figure 42: Time course analysis of the aggregation of Atx-3 13Q and Atx-13Q:NB01 complex (1:2) using DLS.  
A) Aggregation of Atx-3 13Q in full circles and complex in empty circles measured by the increase of light scattering 
intensity in normalized units DLS through time. B) D) F) Atx-3 13Q particle size distribution by DLS. C) D) F) Complex 
particle size distribution by DLS. G) Time evolution of Rh.  The coloration of the circles demonstrates the assay time 
course and it the correspondence in hours is displayed in the top of the panel.  
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The hydrodynamic radius of the first moments of the complex aggregation was 
not detected due to low fibril concentration in the sample (Figure 42G). The initial HMW 
fibril species (100 nm) are prevented in the presence of the NB and the mean 
distribution of fiber size both with and without NB01 is about 15 nm. The species that 
are being formed during the aggregation process of Atx-3 13Q and Atx-3 13Q:NB01 
(1:2) seem to present the same average distribution molecular weight. This indicates 
that the aggregation process occurs through the same mechanism in the presence of 
NB01.  
As mentioned for NB05, additional studies using NB01 are essential to clarify 
the changes in the toxicity caused by this NB. It is also essential to study the effect of 
this nanobody in the expanded form of Atx-3. 
 
 
Size Exclusion Chromatography (Atx-3 77Q:NB01 complex) 
The assay was simultaneously performed for the Atx-3 77Q:NB05 and  
Atx-3 77Q:NB01 complex so both time courses were compared to the same  
Atx-3 77Q control previously presented. With the addition of NB01 (1:2) the monomeric 
fraction of the complex remains present for longer periods, being still identifiable 
140 hours after the start of the aggregation process (Figure 43H). Regarding the 
intermediate oligomeric species, their presence is visible after 92 hours (Figure 43G, 
fraction 6) like the Atx-3 77Q control (Figure 43G). After 166h (Figure 43I) all of the 
complex is present in fraction 7 (with very low absorbance), corresponding to high 
molecular weight oligomers. The aggregation profile for complexes with NB01 is the 
same regardless of the Atx-3 isoform involved in complex formation. Fibril formation 
needs more time to start and takes more time to oligomerize.  
 
Due to the expansion of the lag phase and a prolonged presence of soluble low 
molecular weight species more studies are needed to understand the toxicity resulting 
of the incubation of NBs such as in vivo studies to evaluate the therapeutic relevance 
of this molecular tool on Machado-Joseph disease and to guarantee that there is no 
heightened toxicity.  
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Figure 43: Modulation of the aggregation of 5M Atx-3 77Q by incubation with NB01 (Atx-3:NB01 ration 1:2). 
SEC analysis at different time points (0, 24, 40, 72, 92, 140, 166) indicated by different colors. A) Atx-3 77Q control, B) 
Complex of Atx-3 77Q and NB01 (1:2). Aggregation comparison between Atx-3 77Q and the complex: C) 0 h, D) 24 h, 
E) 40 h, F) 72 h, G) 92 h, H) 140 h, I) 166 h. The aggregation is delayed by the presence of NB01. 
 
In summary, all NBs studied so far increased the lag phase of Atx-3 and the 
elongation phase appears not to be altered. However, only the NBs that can bind to 
Atx-3 77Q can decrease the presence of mature fibers. Toxic species (that are 
recognized by Anti-A11) are still formed, but their detection is similar to the controls. 
NB01 presented a high increase in the aggregation lag phase of Atx-3 13Q and  
Atx-3 77Q and NB05 showed the ability to specifically delay Atx-3 77Q aggregation. 
Based on this information further studies were performed using these NBs. The soluble 
species formed when these NBs are present are identical to the control. Still, these 
results prompt new questions about the toxicity of the NBs and their applicability in the 
Atx-3 aggregation modulation.  
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Conclusions 
The main goal of this work was to explore the potential of NBs produced against 
the Atx-3 JD in modulating the aggregation process of Atx-3 and subsequent 
applicability in the therapy of Machado-Joseph Disease. An additional objective was to 
use these NBs as crystallization chaperones to aid the crystallization and structure 
determination of Atx-3. 
 
The optimal conditions of expression and purification of NBs were determined 
and resulted in the production of high amounts of pure protein for 17 of the 18 NB 
variants under study, except for NB10, which remained insoluble. 
After the production of the 17 NBs a selection of the most promising was done 
via a pull-down assay. This technique provided some promising hits, such as NB01 and 
NB02. The incubation of each NB with different constructs of Atx-3 followed by 
purification of the binary complexes by SEC confirmed the interaction of NB01 and 
NB02 with Atx-3 and revealed another possible Atx-3 interactor, NB05, which was not 
detected by the pull-down assay. The inability to detect this interaction in the pull-down 
assay could be explained by a competitive binding of NB05 and of antibody anti-Atx-3 
1H9 to an overlapping Atx-3 interaction surface. Interestingly, although the NBs were 
produced against JD, no interaction between the isolated Atx-3 JD and the NBs (01, 02 
and 05) was detected.  
Biochemical characterization of the interaction between the three NBs and the 
different Atx-3 isoforms and truncated constructs resulted in the determination of the 
affinity constants, which were in the nanomolar range for the interaction between the 
three Atx-3 interacting NBs and the Atx-3 variants. In accordance with the pull-down 
and the SEC assay, no interaction was detected between the NBs and the isolated Atx-
3 JD by ITC under the conditions tested. The NB that exhibited the highest affinity to 
Atx-3 variants was NB01 with KD = 49.4  6.7 nM for Atx-3 D1, KD =212  9 nM for Atx-
3 13Q and KD = 333  49 nM for Atx-3 77Q. NB02 and NB05 showed similar affinity 
constants (428-911 nM) while no interaction was detected using NB03. Also, the molar 
ratio varied between 1:1 and 1:2 (Atx-3:NB). 
Regarding NB01, there seems to exist a correlation between the size of Atx-3 
(and the PolyQ tract) and the affinity of interaction. The presence of further Atx-3 
domains and the expansion of the polyQ stretch may increase the protein flexibility 
decreasing the affinity for NB01. The absence of interaction with Atx-3 JD may be 
justified by the low affinity or transient nature of this interaction or even by the low 
abundance of a specific Atx-3 conformer to which NB exclusively binds in the 
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conditions tested. This suggests that these NBs may only recognize specific 
conformations of Atx-3 JD that are mainly present in Atx-3 D1, Atx-3 13Q and Atx-3 
77Q, triggered by the dynamic behavior of the structurally disordered C-terminal tail. 
For all three NBs (NB01, 02 and 05) complex formation is governed by enthalpic-driven 
interactions such as hydrogen bonds or polar contacts, suggesting that no major 
structural changes are occurring. 
DLS results combined with SAXS analysis showed that, although Atx-3 protein 
naturally displays an elongated structure, the presence of NB01 confers the complex a 
more compact globular shape. The use of Small Angle X-ray Scattering added an 
important layer of information: the reconstruction of the shape of the complex displays 
2 NB01 bound to 1 Atx-3 13Q molecule. This technique also confirmed the hypothesis 
that no major structural changes occur: The globular shape of the complex does not 
derive from conformational changes in either protein but from the enveloping effect of 
the two NBs. Still, it is not clear whether both NB01 molecules are in fact bound to Atx-
3 or if only one is directly interacting. Additionally, this method does not allow to 
precisely map the Atx-3 interaction site.  
The ability of the NBs to stabilize Atx-3 and induce a more compact structure 
was a good hint of their crystallization chaperone properties. While preliminary 
crystallization conditions were obtained for co-crystallization of Atx-3 D1 with NB01, no 
optimal condition was found. Further optimization of the crystallization conditions is 
required. 
 
The DLS assay gave the first indication that these NBs (NB01 more precisely) 
may be in fact good modulators of Atx-3 aggregation by decreasing of Atx-3 
polydispersity. This finding was then supported by the incubation of Atx-3 constructs 
with three of the NBs (NB01, NB02 and NB05) which resulted in a prolonged lag phase 
of Atx-3 aggregation. This delayed aggregation was not accompanied by alterations in 
the profile of the amyloid progress curves, indicating that the elongation process is not 
affected by the presence of these interactors. NB03 did not present any interaction with 
Atx-3 isoforms during biochemical assays but also delayed Atx-3 aggregation probably 
due to an unspecific molecular crowding effect. 
Considering NB01 specifically, this NB extended the amyloid aggregation lag 
phase of both normal and expanded Atx-3 and decreased the formation of mature 
amyloid mature fibrils of the pathogenic Atx-3, without affecting the formation of 
intermediate species. The oligomeric species that are formed during the lag phase 
present the same size both with and without the addition of NB01. In turn, studies using 
NB05 present an impressive retardation of Atx-3 77Q aggregation and a moderate 
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delay of non-pathogenic (Atx-3 13Q) aggregation. The increase in the lag phase by 
NB05 did not affect the presence of low molecular weight intermediated species. 
Combining this information, it becomes clear that the main effect of the tested NBs on 
Atx-3 is the delay of the aggregation process, probably by shielding the previously 
mentioned aggregation--prone regions (although the exact region of interaction could 
not yet be determined).  
 
Nowadays, the soluble low molecular weight toxic oligomeric species formed 
during the aggregation process of Atx-3 are pointed as the main intermediate species 
causing the neurodegeneration associated with distinct amyloid diseases, such as 
MJD, Parkinson’s and Alzheimer’s. The interaction of the NBs with Atx-3 leads to a 
delay in the aggregation but does not prevent the presence of toxic oligomeric species 
in the endpoint. The toxicity of the soluble intermediates formed in the presence of NBs 
may be different than the species formed with Atx-3 alone. Since we intend to explore 
the potential of NBs in modulating the neurodegeneration resulting from this process, 
additional in vivo studies using an already established MJD neuronal model are 
required to make sure that the beneficial effect of the NBs in the lag phase is not 
cancelled by an increase in overall toxicity. 
 
 Overall, this study provides valuable insights on the biochemical and 
biophysical characterization of the interaction between NBs and Atx-3, clarifying the 
thermodynamics of the binding and absence of structural changes induced by the 
complex formation. Additionally, in vitro experiments revealed that binding of NBs to or 
near the Josephin Domain of Atx-3 results in the delay of the start of the aggregation 
process. As such, this work may be the basis for promising exploration of NBs as 
biopharmaceutical tools in the prevention of Machado-Joseph Disease.  
 
Future Perspectives  
Future perspectives for this work comprise the following topics: to complete the 
characterization of the interaction between the two best NBs (NB01 and NB05) and 
Atx-3 as well as studying the toxicity of the soluble intermediate species that are 
formed during the aggregation process in both non-expanded and expanded Atx-3:NB 
complexes using cell culture techniques. 
It is also essential to demonstrate the ability of these NBs to delay the 
aggregation in a selective and directed manner by mapping the binding site residues of 
the complex. Site-directed mutagenesis studies of the Atx-3 binding site residues may 
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be used to test if the interaction is crucial to the NB effect. Additionally, knowing the 
binding sequence of the NBs we could design even smaller peptides as good 
interactors, with better pharmaceutical properties. 
At last, more efforts need to be done in the crystallography studies of the  
Atx-3:NB complex. The determination of its atomic structure would be an important 
step in the endeavor of fully understanding the molecular properties of Atx-3 and in the 
discovery of new pharmacological approaches. 
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Appendix 
 
Isoform Sequence 
Molecular 
Weight 
Abs 0.1 % 
( 1 g/L) 
Atx-3 JD 
MHHHHHESIFHEKQEGSLCAQHCLNNLLQGEYFSP 
VELSSIAHQLDEEERMRMAEGGVTSEDYRTFLQQPS 
GNMDDSGFFSIQVISNALKVWGLELILFNSPEYQRLRI 
DPINERSFICNYKEHWFTVRKLGKQWFNLNSLLTGP 
ELISDTYLALFLAQLQQEGYSIFVVKGDLPDCEADQL 
LQMIR 
21.86 kDa 1.175 
Atx-3 D1 
MSYYHHHHHHLENLYFQGMESIFHEKQEGSLCAQH 
CLNNLLQGEYFSPVELSSIAHQLDEEERMRMAEGGV 
TSEDYRTFLQQPSGNMDDSGFFSIQVISNALKVWGLE 
LILFNSPEYQRLRIDPINERSFICNYKEHWFTVRKLGK 
QWFNLNSLLTGPELISDTYLALFLAQLQQEGYSIFVV 
KGDLPDCEADQLLQMIRVQQMHRPKLIGEELAQLK 
EQRVHKTDLERVLEANDGSGMLDEDEEDLQRALAL 
SRQEIDMEDEEADLRRTIQLSMQGSSR 
32.58 kDa 0.926 
Atx-3 13Q 
MSYYHHHHHHLENLYFQGMESIFHEKQEGSLCAQH 
CLNNLLQGEYFSPVELSSIAHQLDEEERMRMAEGGV 
TSEDYRTFLQQPSGNMDDSGFFSIQVISNALKVWGLE 
LILFNSPEYQRLRIDPINERSFICNYKEHWFTVRKLGK 
QWFNLNSLLTGPELISDTYLALFLAQLQQEGYSIFVV 
KGDLPDCEADQLLQMIRVQQMHRPKLIGEELAQLK 
EQRVHKTDLERVLEANDGSGMLDEDEEDLQRALAL 
SRQEIDMEDEEADLRRTIQLSMQGSSRNISQDMTQTS 
GTNLTSEELRKRREAYFEKQQQKQQQQQQQQQQG 
DLSGQSSHPCERPATSSGALGSDLGDAMSEEDMLQA 
AVTMSLETVRNDLKTEGKK 
43.58 kDa 0.726 
Atx-3 77Q 
MSYYHHHHHHLENLYFQGMESIFHEKQEGSLCAQH 
CLNNLLQGEYFSPVELSSIAHQLDEEERMRMAEGGV 
TSEDYRTFLQQPSGNMDDSGFFSIQVISNALKVWGLE 
LILFNSPEYQRLRIDPINERSFICNYKEHWFTVRKLGK 
QWFNLNSLLTGPELISDTYLALFLAQLQQEGYSIFVV 
KGDLPDCEADQLLQMIRVQQMHRPKLIGEELAQLK 
EQRVHKTDLERVLEANDGSGMLDEDEEDLQRALAL 
SRQEIDMEDEEADLRRTIQLSMQGSSRNISQDMTQTS 
GTNLTSEELRKRREAYFEKQQQKQQQQQQQQQQQ 
QQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQ 
QQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQ 
RDLSGQSSHPCERPATSSGALGSDLGDAMSEEDML 
QAAVTMSLETVRNDLKTEGKK 
51.88 kDa 0.610 
NB01 - 14.16 1.523 
NB02 - 14.50 1.281 
NB03 - 15.09 2.157 
NB05 - 14.08 1.425 
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Figure 44: NB01 vs Atx-3 variants ITC assay. A) Atx-3 JD vs NB01, B) Atx-3 D1:NB01 in triplicates, C) Atx-3 
13Q:NB01 in triplicates, D) Atx-3 77Q:NB01 in triplicates. Measure of the heat that is released during the NB01 
injections (cal/seg) and experimental data fitting using a non-linear regression. E) Parameter values N (molar ratio), 
KD, H, -TS and G, experimental error of each assay. 
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Figure 45: NB02 vs Atx-3 variants ITC assay. A) Atx-3 JD vs NB02, B) Atx-3 D1:NB02 in triplicates, C) Atx-3 
13Q:NB02 in triplicates, D) Atx-3 77Q:NB02 in triplicates. Measure of the heat that is released during the NB02 
injections (cal/seg) and experimental data fitting using a non-linear regression. E) Parameter values N (molar ratio), 
KD, H, -TS and G, experimental error of each assay. 
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Figure 46: NB03 vs Atx-3 variants ITC assay. A) Atx-3 JD vs NB03, B) Atx-3 D1:NB03 in triplicates, C) Atx-3 
13Q:NB03 in triplicates, D) Atx-3 77Q:NB03 in triplicates. Measure of the heat that is released during the NB03 
injections (cal/seg) and experimental data fitting using a non-linear regression. E) Thermodynamic parameters were 
not calculated due to the absence of signal.  
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Figure 47: NB05 vs Atx-3 variants ITC assay. A) Atx-3 JD vs NB05, B) Atx-3 D1:NB05 in triplicates, C) Atx-3 
13Q:NB05 in triplicates, D) Atx-3 77Q:NB05 in triplicates. Measure of the heat that is released during the NB05 
injections (cal/seg) and experimental data fitting using a non-linear regression. E) Parameter values N (molar ratio), 
KD, H, -TS and G, experimental error of each assay. 
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